Statistical Analysis Plan H8H-CD-LAHF

A Phase I, Multicenter, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Lasmiditan in Subjects with Normal and Impaired Hepatic Function

NCT03040479

Approval Date: 24-Oct-2017

16.1.9 Documentation of Statistical Methods

16.1.9.1. Statistical analysis plan (SAP)

16.1.9.2 Documentation of statistical analysis – SAS® output

16.1.9.1. Statistical analysis plan (SAP)

The statistical analysis plan (SAP) is presented next.

Altasciences
CLINICAL RESEARCH
ALGORITHME PHARMA

STATISTICAL ANALYSIS PLAN

For:

CoLucid Pharmaceuticals, Inc.

SPONSOR PROTOCOL No. COL MIG-114

A Phase I, Multicenter, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Lasmiditan in Subjects with Normal and Impaired Hepatic Function

Algorithme Project No. CUD-P9-453

Prepared by:

Algorithme Pharma
575 Armand-Frappier
Laval, Quebec
Canada, H7V 4B3

Version: Final 1.0

Date: 2017/10/24

Altasciences
CLINICAL RESEARCH
ALGORITHME PHARMA

STATISTICAL ANALYSIS PLAN APPROVAL

We have carefully read this Statistical Analysis Plan and agree it contains the necessary information required to handle the statistical analysis of study data.

PPD

PPD

2017/11/03
Date

PPD

2017/11/03
Date

On behalf of the Sponsor:

PPD

Date

VERSION CONTROL

Version Number	Version Date	Author	Description of Significant Changes from Previous Approved Version
DRAFT 0.1	2017/08/11	PPD PPD	Not Applicable – First Version
DRAFT 0.2	2017/09/29	PPD PPD	Not Applicable – Second Version after the first round of comments
DRAFT 0.3	2017/10/16	PPD PPD	Not Applicable – Third Version after the second round of comments
DRAFT 0.4	2017/10/24	PPD PPD	Not Applicable – Fourth Version after the third round of comments
FINAL 1.0	2017/10/28	PPD / PPD	Final version

CONTENTS

ABBREVIATIONS

AE	Adverse Event
ANOVA	Analysis of Variance
ATC	Anatomical/Therapeutic/Chemical
AUC	Area Under Curve
BMI	Body Mass Index
CI	Confidence Interval
CLCR	Creatinine Clearance
CNS	Central Nervous System
CRF	Case Report Form
CS	Clinically Significant
C-SSRS	Columbia-Suicide Severity Rating Scale
CSR	Clinical Study Report
eGRF	Estimated Glomerular Filtration Rate
EOS	End of Study
ICF	Informed Consent Form
MedDRA	Medical Dictionary for Regulatory Activities
NCS	Not Clinically Significant
PK	Pharmacokinetic(s)
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
SD	Standard Deviation
SE	Standard Error
SOC	System Organ Class
TEAE	Treatment-Emergent Adverse Event
TFLs	Tables, Figures, and Listings
WHO-DDE	WHO Drug Dictionary Enhanced

1. INTRODUCTION

This statistical analysis plan (SAP) provides a detailed description of the statistical methods and procedures to be implemented for the analyses of data from Protocol No. COL MIG-114. The analyses described in the SAP are based upon the final protocol (Fully signed) dated 2017/01/09.

2. STUDY OBJECTIVES

Primary Objectives

The primary objective of this study is to evaluate the pharmacokinetic profile of lasmiditan following a single oral 200 mg dose in subjects with mild and moderate hepatic function relative to matched, healthy controls with normal hepatic function.

Secondary Objective

The secondary objective of this study is to assess the safety and tolerability of a single oral 200 mg dose of lasmiditan in subjects with normal, mild and moderate hepatic function.

3. STUDY DESIGN

General Description

This is a multi-center, open-label, non-randomized, parallel-group, single dose study. This study will enroll up to 24 subjects and will include 2 hepatic impaired subject groups and one group of control subjects with normal hepatic function.

Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered in the study.

Approximately four subjects with mild hepatic impairment will be enrolled first (Group 1). To ensure subject safety, following dosing of these first four subjects, a safety meeting will take place to review the safety data prior to dosing additional subjects. After safety and PK results from the first four subjects have been reviewed, an additional four subjects with mild hepatic impairment (remainder of Group 1) will be enrolled concurrently with the moderated hepatic impairment group (Group 2). Thereafter, matched subjects with normal hepatic function (Group 3) will be enrolled. There will be up to 8 subjects in each of the following groups, based on hepatic function at screening:

- Group 1: Mild hepatic impairment subjects (Child-Pugh Class A: 5 to 6 points)
- Group 2: Moderate hepatic impairment subjects (Child-Pugh Class B: 7 to 9 points)
- Group 3: Healthy subjects with normal hepatic function

All subjects will participate in one treatment period and will receive a single dose of lasmiditan in the fasting state. Subjects will be confined to the clinic from at least 10 hours prior to dosing until 36 hours after drug administration. The total duration of each subject's participation in the study will be 3 days (Day –1 through the last PK sample taken on Day 2), not including the screening and follow-up phone call. Study procedures

For complete details on the study assessments to be performed for the study, refer to Appendix A.

Randomization and Unblinding Procedure

No randomization will be performed for this study
No unblinding procedure is required, as this in an open-label study.

4. STUDY ENDPOINTS

Pharmacokinetic Endpoints

The following plasma PK parameters of lasmiditan will be calculated: C_{max}, T_{max}, $AUC_{(0\text{-}tlast)}$, $AUC_{(0\text{-}\infty)}$, $\%AUC(t_{last}\text{-}\infty)$, λ_z, $T_{1/2}$, CL/F, V_z/F.

Safety Endpoints

Safety endpoints include:

- Adverse Events
- Clinical Laboratory Tests (hematology, chemistry, urinalysis)
- Vital Signs
- Physical examination
- Concomitant medication
- 12 Lead ECGs
- C-SSRS

The details of the safety endpoints' assessment are presented in Section 10.

Sample Size Determination

There is no formal statistical sample size calculation for this study. A sample size of 24; including 8 subjects/patients for each hepatic function group (8 subjects with normal hepatic function, 8 patients with mildly impaired hepatic function and 8 patients with moderately impaired hepatic function) was chosen because it is considered typical for studies evaluating the effect of hepatic function on the pharmacokinetics of a drug..

5. ANALYSIS POPULATIONS

Safety Population:

All subjects who received a dose of study medication will be included in the safety population. This population will be used for all demography and safety analyses.

Pharmacokinetics (PK) Population:

All subjects who received lasmiditan, had no major protocol deviations, and completed the period with evaluable (sufficient and interpretable) data will be included in the PK population.

If some subjects do not complete the sampling schedule resulting in an inadequately characterized some PK parameters (e.g. AUC, V_Z/F, λ_Z), samples of these subjects could be included in the statistical pharmacokinetic analysis for only the evaluable parameters

6. STATISTICAL METHODOLOGY

All analyses will be conducted using the SAS software, version 9.4, or higher. Descriptive statistics of the PK data will be performed by Phoenix® WinNonlin® version 6.3 or higher, Phoenix® ConnectTM version 1.3.1 or higher).

Adverse events and medical history will be classified using the standard MedDRA terminology version 19.1.

Prior and concomitant medications will be coded with the WHO-DDE dictionary version March 01, 2016.

In general, all summary tables will be presented for safety population. Summaries will be presented by hepatic function group.

In general, the data listings will include all enrolled subjects up to the point of study completion or discontinuation; exceptions will be listings pertaining to a subset of subjects only (e.g., subjects with blood sampling time deviations) or a subset of records/events (e.g., abnormal laboratory values).

Categorical variables will be summarized using the PROC FREQ procedure. Continuous variables will be summarized using the PROC UNIVARIATE procedure. For log-transformed endpoints, geometric mean, and coefficient of variation will also be presented.

The following general comments also apply to all statistical analyses and data presentations:

- Duration variables in days will be calculated using the general formula: (end date - start date) +1.
- Individual subject listings of all data represented on the CRFs will be provided to facilitate the investigation of tabulated values and to allow for the clinical review of all efficacy and safety parameters.
- When assessments are repeated for a given timepoint, only the result which is closes to the dosing time will be included in the summary tables.

The analyses described in this plan are considered a priori, that they have been defined prior to database lock. Any analyses performed subsequent to database lock will be considered post hoc and exploratory. Post hoc analyses will be labeled as such in the corresponding statistical output and identified in the CSR.

Analysis Time Points

Unless otherwise specified, the baseline value will be defined as the last non-missing evaluation prior to the first dose of study medication.

Methods for Handling Missing Data

No imputations of values for missing data will be performed. All data recorded on the case report form will be included in the listings that will accompany the clinical study report.

7. STUDY SUBJECTS

Disposition

The subject disposition will be summarized for all subjects enrolled in this study, including:

- The number of subjects enrolled;
- The number of screen failure subjects;
- The number of subjects screened;
- The number and percentage of subjects who completed the study;
- The number and percentage of subjects discontinued from the study by primary reason for discontinuation and overall;
- The number and percentage of subjects included in each of the safety and PK populations.

The percentages will be calculated using the number of subjects randomized as denominator.

A listing of subject's disposition will be provided. A listing of subjects included in each of the analysis populations will also be provided. Screen failure subjects will also be presented in a listing.

Protocol Deviations

Inclusion/exclusion criteria violations will be presented in a listing.

All deviations from the scheduled PK sampling time of 2 minutes or more for post dose samples will be taken into consideration for the evaluation of PK parameters.

8. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

Demographic and Background Characteristics

Demographic data and baseline characteristics will be presented in a data listing and summarized by hepatic function group in a table. Quantitative assessments to be summarized are age, height, body weight and body mass index (BMI) at screening. Subject demographics include sex, age, ethnicity, race and country. Baseline characteristics include height, weight, and BMI.

Lifestyle

Alcohol and smoking intake history will be recorded and presented in separate listings.

Medical/Social history

Any medical history findings will be recorded and presented in a listing. The listing will include the coding terms (e.g., SOC and Preferred Term).

Prior Medication

Any medications taken including prescription, nonprescription, OTC (cold and antacid medications), dietary supplements, vitamins or herbal medications from screening to the first dose of the study drug will be recorded and presented as prior medications in a listing. The listing will include the coding terms (e.g., ATC and Preferred Term).

9. PHARMACOKINETICS AND STATISTICS

Pharmacokinetic Analysis

The PK parameters are presented in Section 4 and Appendix B. All reported sampling time deviations (see Section 7) will be taken into consideration for evaluation of plasma PK parameters.

Only quantifiable concentrations will be used to calculate PK parameters. An exception to this rule is made for concentrations below the quantification limit (BQL), which will be set to zero when all of the following conditions are met:

The time points occur before the first quantifiable concentration. All other BQL concentrations will be treated as missing sample.

The pharmacokinetic parameters will be estimated using a non-compartmental approach with a log-linear terminal phase assumption. The trapezoidal rule will be used to estimate the area under the curve, and the terminal phase will be estimated by maximizing the coefficient of determination estimated from the log-linear regression model. These parameters ($AUC_{(0-\infty)}$, %AUC(tlast-∞), λ_z, $T_{1/2}$, CL/F and Vz/F) will be estimated for individual concentration-time profiles only when the terminal log-linear phase cannot be reliably characterized using the following criteria:

- Phoenix® WinNonlin® Best fit range selection:
- R2 of at least 80%

In the case where less than 3 consecutive measurable plasma concentrations of lasmiditan are observed, the AUC parameters will not be estimated.

Additional pharmacokinetic parameters may be calculated if deemed appropriate.

Pharmacokinetic analyses and associated descriptive statistics will be generated using Phoenix® WinNonlin® Version 6.3 (or higher).

Statistical Analysis

The natural logarithmic transformation of C_{max}, $AUC_{(0\text{-}tlast)}$, $AUC_{(0-\infty)}$, λ_z, CL/F and V_z/F will be used for all statistical inference.

Statistical analyses will be generated using validated SAS® (version 9.4 or higher) using the Reg (and Mixed, if applicable) procedure(s).

Regression Analysis

The Child-Pugh classification at baseline will be used as the primary measure of hepatic function for a regression analysis to evaluate the relationships between estimated hepatic function and PK parameters. Hepatic function in affected subjects will be entered in separate regression models as the following:

- Individual Child-Pugh scores;
- Hepatic Impairment Group:
    1. Child-Pugh classification A;
    2. Child-Pugh classification B;
    3. Subject with normal hepatic function

For each PK parameter except T_{max}, a regression analysis will be performed to assess the impact of impaired Hepatic Function, using a regression model of the form $\alpha + \beta$*(Hepatic Function) + ε where the errors (ε) will be assumed to be independent and normally distributed with mean zero and variance $\sigma 2$. The parameter β represents the correlation between the relevant PK parameter and the Hepatic Function which will be treated as a continuous variable.

Non-parametric methods based on the Wilcoxon rank sum test will be used to analyze differences in T_{max} between Hepatic Impairment Groups. The rank-transformed T_{max} will be used as the dependent variable in a regression model to analyze the relationship between Individual Child-Pugh score and T_{max}.

The following is the SAS code for the regression model including the individual Child-Pugh scores as Hepatic Function:

```
Proc Reg;
   Model PKparam = HepaticFunction;
Run;
```

Where HepaticFunction is individual Child-Pugh scores and PKparam is the value of the non-log-transformed or log transformed PK parameter.

The following is the SAS code for the regression model including the Hepatic Impairment Group as Hepatic Function:

```
Proc Reg;
   Model PKparam = GrpA GrpB;
Run;
```

Where HepaticFunction is Individual Child-Pugh scores in the first regression model and Hepatic Impairment Group in the second regression model and PKparam is the value of the non-log-transformed or log transformed PK parameter.

The hypothesis of the slope of trend being different from zero will be assumed if the two-sided test of the nullity of the parameter β is statistically significant at the 5% level.

Analysis of Variance

The effect on the pharmacokinetic parameters of the hepatic function will be done including the measurement of the hepatic function and using an analysis of variance (ANOVA). The ANOVA model will include the 3 groups of subjects (2 Child-Pugh classification groups and healthy volunteers) entered as fixed effects.

Pairwise comparisons of the 3 groups will be generated using the Tukey-Kramer's procedure of adjustment for multiple comparisons and statistical significance will be assessed at the two-sided 5% level. Heterogeneity of variance among groups will be assumed. Individual contrasts as well as the corresponding 90% confidence interval comparing each group will be computed.

```
Proc Mixed;
   Class FunctionGroup;
   Model PKparam = FunctionGroup;
   Repeated / Group = FunctionGroup;
   LSmeans FunctionGroup/ Pdiff=All CL Alpha=0.1 Adjust=Tukey;
Run;
```

Where FunctionGroup is the Hepatic Impairment Group and PKparam is the value of the non-log-transformed C_{max}, $AUC_{(0\text{-}tlast)}$, $AUC_{(0\text{-}\infty)}$ or the log transformed C_{max}, $AUC_{(0\text{-}tlast)}$, $AUC_{(0\text{-}\infty)}$.

Non-parametric methods will be used to analyze differences in T_{max} between the Mild and Moderate groups and the Normal group. In addition to the group-specific medians and ranges, the Hodges-Lehmann median, 90% CIs and p-values for the difference based on the Wilcoxon rank sum test statistic will be presented.

10. SAFETY

Adverse Events

An AE is defined as any untoward medical occurrence in a subject administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product.

A suspected adverse reaction is any adverse event for which there is a reasonable possibility that the drug caused the adverse event. 'Reasonable possibility' means there is evidence to suggest a causal relationship between the drug and the adverse event. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse reaction, which means any adverse event caused by a drug.

AEs occurring after the initiation of the treatment are referred to as treatment emergent adverse events (TEAEs).

As an overall summary of AEs, the following will be presented by hepatic function group and overall:

- Number of reported AEs;
- Number of reported TEAEs;
- Number and percentage of subjects experiencing TEAEs;
- Number and percentage of subjects experiencing a drug-related TEAE (i.e. those with a relationship classified as reasonable possibility)
- Number and percentage of TEAEs by relationship to study treatment (i.e. reasonable possibility, no reasonable possibility);
- Number and percentage of TEAEs by severity;
- Number of reported SAEs (serious adverse events);
- Number and percentage of subjects experiencing SAEs;
- Number and percentage of subjects experiencing drug-related SAEs;
- Number and percentage of TEAEs leading to withdrawal; and
- SAEs with an outcome of death.

Frequency tables will be presented hepatic function group, system organ class and preferred term that summarize all Treatment Emergent Adverse Events (TEAEs) and all drug-related TEAEs.

Subject listings of all Adverse Events (AEs) including severity and relationship to study drug will be provided. AEs leading to withdrawal and SAEs will also be presented in separate listings.

Concomitant Medications

Medications taken after the first dose of study drug until after discharge from the study will be recorded. Concomitant medications will be presented in a listing. The medication name, active ingredient, dose, units, formulation, route, indication or reason taken, code, date and time taken will be presented. The listing will also include the coding terms (e.g., ATC and Preferred Term).

Extent of Exposure

Details of drug dosing (actual treatment received, actual date and time of administration, dose administered, and route of administration) will be listed by subject.

Clinical Laboratory Evaluations

Planned laboratory analyses include:

- General Biochemistry: Sodium, potassium, chloride, glucose, blood urea nitrogen (BUN), creatinine, ClCr, eGFR, total bilirubin, alkaline phosphatase, Uric Acid at screening, AST, ALT and albumin;
- Hematology: White cell count with differential (absolute values of neutrophil, lymphocyte, monocyte, eosinophil, and basophil), red cell count, hemoglobin, hemoglobin A1c, hematocrit, mean corpuscular volume (MCV), and platelets count;
- Urinalysis: Color, appearance, specific gravity, pH, leukocyte, protein, glucose, ketones, bilirubin, blood, nitrite, urobilinogen. Microscopic examination will only be performed if the dipstick test is outside of the reference range for leukocyte, blood, nitrite or protein
- Other: serology, Endocrinology, urine drug screen and serum pregnancy.

Hematology, chemistry and quantitative urinalysis laboratory test results will be summarized by hepatic function group, parameter and visit and will also be presented in a listing

Separate listings of for serology, Endocrinology, urine drug screen and serum pregnancy will also be provided.

Subject listings of abnormal on-study laboratory values will be provided. Similarly, clinically significant on-study laboratory data will be presented in a second listing.

Vital Signs

Vital signs will include the measurement of blood pressure, pulse rate, body temperature, and orthostatic blood pressure.

For all vital signs, raw values, at each time point will be summarized by hepatic function group, parameter and visit. Vital signs data will also be presented in a listing.

Subject listing of abnormal on-study vital signs values (Out-of-Range – Not Clinically Significant (NCS) or Clinically Significant (CS)) will be provided. Similarly, CS on-study vital signs values (Out-of-Range – CS) will be presented in a second listing.

Electrocardiogram

A 12-lead ECG will be obtained throughout the study. In some cases, repeat abnormal ECGs may be obtained.

Raw values at each time point will be summarized by hepatic function group, parameter and visit and will also be presented in a listing. Overall safety assessment will also be presented in the listing.

A subject listing of abnormal on-study ECG assessments (Abnormal – NCS or Abnormal – CS) will be provided. Similarly, CS on-study ECG assessments (Abnormal – CS) will be presented in a second listing.

Physical Examination Findings

A physical examination will be conducted and will be presented in a listing.

Columbia-Suicide Severity Rating Scale (C-SSRS)

The Columbia-Suicide Severity Rating Scale (C-SSRS) is a suicidal ideation rating scale. The scale identifies behaviors and thoughts that are associated with an increased risk of suicidal actions in the future.

Subjects who answer 'Yes' to any of the questions on the C-SSRS questionnaire will be presented in a listing.

11. INTERIM ANALYSES AND DATA SAFETY MONITORING

Approximately four subjects with mild hepatic impairment will be enrolled first (Group 1). To ensure subject safety, following dosing of these first four subjects, a safety meeting will take place to review the safety data prior to dosing additional subjects. After safety and PK results from the first four subjects have been reviewed, an additional four subjects with mild hepatic impairment (remainder of Group 1) will be enrolled concurrently with the moderated hepatic impairment group (Group 2). Thereafter, matched subjects with normal hepatic function (Group 3) will be enrolled.

12. CHANGES TO PROTOCOL-SPECIFIED ANALYSES

There is no change from the planned analysis described in the protocol.

13. GENERAL INFORMATION RELATED TO DATA PRESENTATIONS

Safety

All programs used to generate statistical analyses will be validated according to Algorithme Pharma's standard operating procedures.

TFLs will be displayed on letter size paper, 8 ½ inches by 11 inches, using the Courier New font.

In general, summary statistics for raw variables (i.e., variables measured at the study site or central laboratory) will be displayed as follows: if required minima, maxima, means, quartiles, standard deviations and confidence limits will be displayed to the same number of decimal places as the raw data; if required medians will be displayed to one additional decimal place.

Percentages will be displayed to one decimal place. Percentages between 0 and 0.1 (exclusive) will be displayed as '<0.1'. P-values will be displayed to 3 decimal places. P-values that are less than 0.001 will be displayed as '<0.001'.

The numbers of decimal places for summary statistics of derived variables (i.e., variables that are not measured by the study site but are calculated for analysis based on other measured variables) will be determined on a case by case basis. In general, minima and maxima will be displayed to the commonly used unit of precision for the parameter. Means, medians, quartiles, and confidence limits will be displayed to one additional decimal place and standard deviations will be displayed to two additional decimal places.

The formats and layouts of TFLs are provided in subsequent sections. Actual formats and layouts may be altered slightly from those presented in the templates as necessary to accommodate actual data or statistics. Minor format changes will not require updates to the SAP.

The tables and listings listed below are common data displays. Their numbering and general content follow the ICH E3 guidelines. Some of the tables and listings may not be applicable/appropriate/necessary for a particular study. Additional tables and listings may be included, provided the numbering scheme remains consistent with ICH E3.

PK Data

All programs used to generate statistical analyses will be validated according to Algorithme Pharma's standard operating procedures.

TFLs will be displayed on letter size paper, 8 ½ inches by 11 inches, using the Courier New font.

Raw variables (i.e., variables measured at the study site or central laboratory) will be displayed with the same number of decimal places as received as per bioanalytical laboratory. Derived variables (i.e., variables that are not measured by the study site but are calculated for analysis based on other measured variables) will be displayed as follow:

- All calculated pharmacokinetic parameter values should be reported to three significant digits.
- Observed concentration data, e.g. C_{max}, should be reported as received.
- Observed time data, e.g. T_{max}, should be reported as received.
- N should be reported as whole numbers
- Percentage values should be reported with whole numbers, except for the %AUC(tlast-∞).
- Median values should be treated as an observed parameter and reported to the same number of decimal places as minimum and maximum values.

Summary statistics of raw variables: minima, mean, geometric mean, median, maxima, and standard deviation, coefficient of variation will be displayed with the same number of decimal places as the raw data;

- The following summary statistics will be listed for all variables except T_{max} and $T_{1/2}$, arithmetic mean, SD, and CV; geometric mean and CV; N, minimum, maximum, and median.
- Summary statistics for T_{max}, and other discrete parameters, will be limited to N, minimum, maximum, and median. Report not calculated (NC) for other statistics
- Summary statistics for $T_{1/2}$ will be limited to geometric mean and CV; N, minimum, maximum, and median. Report not calculated (NC) for other statistics.

Summary statistics of derived variables will be displayed with the same number of decimal places as the derived variable.

PLANNED TABLES

Demographic Data

Table 14.1.1	Subject Disposition – All Subjects
Table 14.1.2.1	Summary of Demographic Characteristics (Safety Population)
Table 14.1.2.2	Summary of Demographic Characteristics (Pharmacokinetic Population)

Pharmacokinetic Data

Table 14.2.1	Statistical Analysis – SAS output

Safety Data

Tables in this section are based on the safety population unless otherwise stated.

Table 14.3.1.1	Summary of Adverse Events
Table 14.3.1.2	Summary of Treatment Emergent Adverse Events by System Organ Class and MedDRA Preferred Term
Table 14.3.1.3	Summary of Drug-Related Treatment Emergent Adverse Events by System Organ Class and MedDRA Preferred Term
Table 14.3.2.1	Listing of Deaths, Other Serious and Significant Adverse Events
Table 14.3.2.2	Listing of Treatment Emergent Adverse Events Leading to Withdrawal
Table 14.3.4.1	Listing of Abnormal On-Study Laboratory Values
Table 14.3.4.2	Listing of Clinically Significant On-Study Laboratory Values
Table 14.3.4.3	Summary of Blood Chemistry
Table 14.3.4.4	Summary of Hematology
Table 14.3.4.5	Summary of Quantitative Urinalysis
Table 14.3.5.1	Listing of Abnormal On-Study Vital Signs Values
Table 14.3.5.2	Listing of Clinically Significant On-Study Vital Signs Values
Table 14.3.5.3	Summary of Vital Signs
Table 14.3.6.1	Listing of Abnormal On-Study ECG Assessments
Table 14.3.6.2	Listing of Clinically Significant On-Study ECG Assessments
Table 14.3.6.3	Summary of ECG Assessments

In text Tables:

PK Parameters of Lasmiditan

Summary of Statistical Analysis of Lasmiditan

In text Figures:

Linear Profile of the Mean for Lasmiditan

Logarithmic Profile of the Mean for Lasmiditan

Linear Regression of ln-Transformed C_{max} vs Child-Pugh scores

Linear Regression of ln-Transformed $AUC_{(0-\infty)}$ vs Child-Pugh scores

In text Figures (Section 14):

Linear Regression of ln-Transformed $AUC_{(0-tlast)}$ vs Child-Pugh scores

Linear Regression of ln-Transformed CL/F vs Child-Pugh scores

Appendix 16.2.6.1	PK Tables – Plasma - Table X. Measured Human Plasma Concentrations - Table X. Cumulative Area Under the Curve - Table X. Pharmacokinetic Parameters X. Elimination Parameters - Table X. Actual Sampling Time
Appendix 16.2.6.2	PK – Figures - Figure x: Linear Profile of the Mean - Figure x: Logarithmic Profile of the Mean - Figure x: Individual Linear Profile of Subject x - Figure x: Individual Logarithmic Profile of Subject - Figure x: Individual Elimination Profiles

PLANNED LISTINGS

Listing 16.2.1	Listing of Study Disposition
Listing 16.2.2.1	Listing of PK Blood Sampling Time Deviations
Listing 16.2.2.2	Listing of Protocol Deviations
Listing 16.2.3	Listing of Analysis Populations
Listing 16.2.4.1	Listing of Demographic Characteristics
Listing 16.2.4.2	Listing of Screen Failure Subjects
Listing 16.2.5	Listing of Investigational Product Administration
Listing 16.2.7	Listing of Adverse Events
Listing 16.2.8.1	Listing of Blood Chemistry
Listing 16.2.8.2	Listing of Hematology
Listing 16.2.8.3	Listing of Urinalysis
Listing 16.2.8.4	Listing of Urine Drug Screen
Listing 16.2.8.5	Listing of Pregnancy Test
Listing 16.2.8.6	Listing of Serology
Listing 16.2.8.7	Listing of Endocrinology
Listing 16.2.9.1	Listing of Alcohol Habits
Listing 16.2.9.2	Listing of Smoking Habits
Listing 16.2.9.3	Listing of Prior Medication
Listing 16.2.9.4	Listing of Concomitant Medication
Listing 16.2.9.5	Listing of Physical Examination
Listing 16.2.9.6	Listing of Vital Signs
Listing 16.2.9.7	Listing of ECG Assessments
Listing 16.2.9.8	Listing of Inclusion/Exclusion Criteria Summary
Listing 16.2.9.9	Listing of Medical History
Listing 16.2.9.10	Listing of Columbia-Suicide Severity Rating Scale (C-SSRS)

APPENDIX A

STUDY SCHEDULE

Examination	Screening	Days			Post-Study Tests or ET[a]	End of Study
	Day 28 to – 1	-1	1	2	2	7 (±3)
Review Inc/Exclusion Criteria & MedicalHistory	X					
Informed Consent	X					
Check-in		X				
Dosing			X			
Clinic Confinement		X	X	X		
Discharge				X		
Demographics	X					
C-SSRS questionnaire	X				X	
Concomitant Medication	X	X	X	X	X	X
Physical Examination	X				X	
Vital Signs[b]	X		X		X	
Height, Weight, and BMI	X					
12-lead ECG[c]	X		X		X	
HIV Ag/Ab Combo, HBsAg (B) (Hepatitis B) and HCV (C) Tests	X					
Drug and Alcohol Screen	X	X				
Pregnancy test (females)	X	X			X	
Clinical Laboratory Evaluations[d]	X	X			X	
PK Blood Sample[e]			X	X		
Follow-up Call						X
Adverse Events Recording	X	X	X	X	X	X

a Early Termination (ET).
b Vital signs will be measured prior to dosing and approximately 2 and 4 hours after study drug administration.
c 12-lead ECG will be performed prior to dosing and approximately 2 hours after study drug administration.
d Clinical laboratory tests (hematology, biochemistry, endocrinology (screening only) and urinalysis) will be performed. On Day -1, these will be done in the evening prior to drug administration.
e PK blood and urine samples will be collected according to schedule of PK assessments

APPENDIX B

Pharmacokinetic Parameters

PK Parameter	Definition
C_{max}	Maximum observed plasma concentration
T_{max}	Time of maximum observed plasma concentration; if it occurs at more than one time point, T_{max} is defined as the first time point with this value
$AUC_{(0\text{-}tlast)}$	Cumulative area under the plasma concentration time curve calculated from 0 to T_{LQC} using the linear trapezoidal method, where T_{LQC} represents time of last observed quantifiable plasma concentration
$AUC_{(0\text{-}\infty)}$	Area under the plasma concentration time curve extrapolated to infinity, calculated as $AUC_{(0\text{-}tlast)} + \hat{C}_{LQC}/\lambda_Z$, where $\hat{C}_{LQC}$ is the estimated concentration at time T_{LQC}
$\%AUC(t_{last}\text{-}\infty)$	Relative percentage of $AUC_{(0\text{-}tlast)}$ with respect to $AUC_{(0\text{-}\infty)}$ $\%\,AUC(t_{last}\text{-}\infty) = 100 \times \frac{(AUC(0\text{-}\infty) - AUC(0\text{-}t_{last}))}{AUC(0\text{-}\infty)}$
λ_Z	Apparent elimination rate constant, estimated by linear regression of the terminal linear portion of the log concentration *versus* time curve
$T_{1/2}$	Terminal elimination half-life, calculated as $\ln(2)/\lambda_Z$
CL/F	Apparent Total Plasma Clearance, calculated as dose $/AUC_{(0\text{-}\infty)}$
V_z/F	Apparent Volume of Distribution, calculated as dose $/ \lambda_Z * AUC_{(0\text{-}\infty)}$

APPENDIX C

TABLE SHELLS

Table 14.1.1
Subject Disposition
(All Subjects)

		Healthy Hepatic Function (N=XX)	Mild Hepatic Function (N=XX)	Moderate Hepatic Function (N=XX)	Overall (N=XX)
Subjects Enrolled		xx	xx	xx	xx
Screen Fail Subjects		xx	xx	xx	xx
Subjects Screened [N]		xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Subjects Completed the Study [n(%)]	YES	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	NO	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
If No, Reason of Study Discontinuation [n(%)]	Reason 1	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	Reason 2	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	Reason 3	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	Etc.	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Number of Subjects Included in Each Analysis Population [n(%)]	Safety Population	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	Pharmacokinetic Population	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)

Note: The percentages are based on the number of subjects screened.

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Table 14.1.2.1
Summary of Demographic Characteristics
(Safety Population)

		Healthy Hepatic Function (N=XX)	Mild Hepatic Function (N=XX)	Moderate Hepatic Function (N=XX)	Overall (N=XX)
Age (years)	N	xx	xx	xx	xx
	Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	Median	xx.x	xx.x	xx.x	xx.x
	Min, Max	xx, xx	xx, xx	xx, xx	xx, xx
Gender [n(%)]	MALE	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	FEMALE				
Ethnicity [n(%)]	HISPANIC/LATINO	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	NOT HISPANIC/NOT LATINO	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Race [n(%)]	RACE1	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	RACE2	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	Etc.	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Weight (kg)	N	xx	xx	xx	xx
	Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	Median	xx.x	xx.x	xx.x	xx.x
	Min, Max	xx, xx	xx, xx	xx, xx	xx, xx
Height (cm)	N	xx	xx	xx	xx
	Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	Median	xx.x	xx.x	xx.x	xx.x
	Min, Max	xx, xx	xx, xx	xx, xx	xx, xx
Body Mass Index(kg/m^2)	N	xx	xx	xx	xx
	Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
	Median	xx.x	xx.x	xx.x	xx.x
	Min, Max	xx, xx	xx, xx	xx, xx	xx, xx

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Similar Table:

Table 14.1.2.2 Summary of Demographic Characteristics (Pharmacokinetic Population)

Table 14.3.1.1
Summary of Adverse Events
(Safety Population)

	Healthy Hepatic Function (N=XX)	Mild Hepatic Function (N=XX)	Moderate Hepatic Function (N=XX)	Overall (N=XX)
Adverse Events (AEs) Reported [n]				xx
Treatment Emergent Adverse Events (TEAEs) Reported [n]	xx	xx	xx	xx
Subjects With At Least One TEAE [n(%)] [1]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Subjects With At Least One Drug-Related TEAE [n(%)] [1] [3]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
TEAEs Relationship [2]				
Related [n(%)] [3]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Not Related [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
TEAEs Severity/Intensity [2]				
Mild [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Moderate [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Severe [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Life-Threatening [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Serious Adverse Events (SAEs) Reported [n] [2]	xx	xx	xx	xx
Subjects With At Least One SAE [n(%)][1]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Subject With an TEAE Leading to Withdrawal [n(%)] [1]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)
Death [n(%)] [1]	xx (xx.x)	xx (xx.x)	xx (xx.x)	xx (xx.x)

[1] Percentages are based on the number of subjects in the Safety population in each treatment group.
[2] Percentages are based on the total number of treatment emergent adverse events reported in each treatment group.
[3] TEAE that was reported with a relationship of "reasonable possibility".

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Table 14.3.1.2
Summary of Treatment Emergent Adverse Events by System Organ Class and MedDRA Preferred Term
(Safety Population)

SOC MedDRA Preferred Term	Healthy Hepatic Function (N=XX)	Mild Hepatic Function (N=XX)	Moderate Hepatic Function (N=XX)
Subjects With At Least One TEAE [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)
System Organ Class 1 [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)
MedDRA Term 11 [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)
MedDRA Term 12 [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)
MedDRA Term 13 [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)
System Organ Class 2 [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)
MedDRA Term 21 [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)
MedDRA Term 22 [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)
MedDRA Term 23 [n(%)]	xx (xx.x)	xx (xx.x)	xx (xx.x)
Etc.	xx (xx.x)	xx (xx.x)	xx (xx.x)

Note: Each treatment emergent adverse event is counted only once for each subject within each System Organ Class and MedDRA Preferred Term.

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Similar Table: Table 14.3.1.3 Summary of Drug-Related Treatment Emergent Adverse Events by System Organ Class and MedDRA Preferred Term

Table 14.3.2.1
Listing of Deaths, Other Serious and Significant Adverse Events
(Safety Population)

Subject ID	Visit/ Group/ AE #	SOC MedDRA Preferred Term Description of AE	Onset Date Time (Time since Last Dose)	Resolution Date Time (Duration)	S: Severity R: Relationship to Study Drug	O: Outcome S: Serious AE D: AE Leading To Discontinuation	Action Taken With Treatment / Other Action(s) Taken / Concomitant Given
		xxxxxxxxxxxx xxxxxxxxxxxx	YYYY-MM-DD/ HH:MM	YYYY-MM-DD/ HH:MM			
xxx	xxxxx	xxxxxxxxxxxx	(DD:HH:MM)	(DD:HH:MM)	xxxxxx	xxxxx	xxxxxx

Similar Tables:
14.3.2.2 Listing of Treatment Emergent Adverse Events Leading to Withdrawal

Table 14.3.4.1
Listing of Abnormal On-Study Laboratory Values
(Safety Population)

Category/ Parameter (Unit)	Reference Range	Subject ID	Visit	Date / Time	Value	Out-of-Range Flag	Assessment [1]
Lab Category 1							
Lab Test 11	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx
Lab Test 12	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx
Lab Category 2							
Lab Test 21	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx
Lab Test 22	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx
Etc.	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx

[1] NCS: Not Clinically Significant / CS: Clinically Significant / TBC: To Be Controlled.
Note(s): Abnormal values are determined by applying the reference ranges to the results as reported by the external laboratory analysis.

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Table 14.3.4.2
Listing of Clinically Significant On-Study Laboratory Values
(Safety Population)

Category/ Parameter (Unit)	Reference Range	Subject ID	Visit	Date / Time	Value	Out-of-Range Flag	Assessment [1]
Lab Category 1							
Lab Test 11	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx
Lab Test 12	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx
Lab Category 2							
Lab Test 21	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx
Lab Test 22	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx
Etc.	xxx-xxx	xxx	xxxxxx	xxxxxx	xxx	xxx	xxx

[1] CS: Clinically Significant / TBC: To Be Controlled.
Note(s): Abnormal values are determined by applying the reference ranges to the results as reported by the external laboratory analysis.

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Table 14.3.4.3
Summary of Blood Chemistry
(Safety Population)

Parameter (unit)	Visit Name		Statistic	Healthy Hepatic Function (N=XX)	Mild Hepatic Function (N=XX)	Moderate Hepatic Function (N=XX)
xxx (xxx)	Screening	Value	N	xx	xx	xx
			Mean (SD)	xx.x (xx.xx)	xx.x (xx.xx)	xx.x (xx.xx)
			Median	xx.x	xx.x	xx.x
			Min, Max	xx, xx	xx, xx	xx, xx
	Day -1	Value	N	xx	xx	xx
			Mean (SD)	xx.x (xx.xx)	xx.x (xx.xx)	xx.x (xx.xx)
			Median	xx.x	xx.x	xx.x
			Min, Max	xx, xx	xx, xx	xx, xx
	Etc.		N	xx	xx	xx
			Mean (SD)	xx.x (xx.xx)	xx.x (xx.xx)	xx.x (xx.xx)
			Median	xx.x	xx.x	xx.x
			Min, Max	xx, xx	xx, xx	xx, xx

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Similar Tables:
14.3.4.4 Summary of Hematology
14.3.4.5 Summary of Quantitative Urinalysis

Table 14.3.5.1
Listing of Abnormal On-Study Vital Signs Values
(Safety Population)

Assessment (Units)	Subject ID	Visit	Position	Date / Time	Value	Safety Review
Vital Sign Test 1	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx
	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx
Vital Sign Test 2	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx
	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx
Etc.	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Table 14.3.5.2
Listing of Clinically Significant On-Study Vital Signs Values
(Safety Population)

Assessment (Units)	Subject ID	Visit	Position	Date / Time	Value	Safety Review
Vital Sign Test 1	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx
	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx
Vital Sign Test 2	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx
	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx
Etc.	xxx	xxxxxx	xxxxxx	YYYY-MM-DD:XX:XX	xxx	xxx

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Table 14.3.5.3
Summary of Vital Signs
(Safety Population)

Parameter (unit)	Visit	Timepoint		Statistic	Healthy Hepatic Function (N=XX)	Mild Hepatic Function (N=XX)	Moderate Hepatic Function (N=XX)
Vital Sign Test 1							
	Screening		Value	N	xx	xx	xx
				Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)
				Median	xx.x	xx.x	xx.x
				Min, Max	xx, xx	xx, xx	xx, xx
	Day 1	2 Hours	Value	N	xx	xx	xx
				Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)
				Median	xx.x	xx.x	xx.x
				Min, Max	xx, xx	xx, xx	xx, xx
	Day 1	4 Hours	Value	N	xx	xx	xx
				Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)
				Median	xx.x	xx.x	xx.x
				Min, Max	xx, xx	xx, xx	xx, xx
Etc.	Etc.						

PROGRAMMING NOTE: All visits outlined in Appendix A will be included.

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Table 14.3.6.1
Listing of Abnormal On-Study ECG Assessments
(Safety Population)

Subject ID	Visit	Time Point	Date / Time	Position	Safety Review	Parameter (Unit)	Value
xxxxx	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
xxxxx	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
xxxxx	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Table 14.3.6.2
Listing of Clinically On-Study ECG Assessments
(Safety Population)

Subject ID	Visit	Time Point	Date / Time	Position	Safety Review	Parameter (Unit)	Value
xxxxx	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
xxxxx	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
xxxxx	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
xxxxx	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
xxxxx	xxxxxx	xxx	YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Table 14.3.6.3
Summary of ECG Assessments
(Safety Population)

Parameter (unit)	Visit	Timepoint		Statistic	Healthy Hepatic Function (N=XX)	Mild Hepatic Function (N=XX)	Moderate Hepatic Function (N=XX)
ECG Assessment Test 1							
	Screening		Value	N	xx	xx	xx
				Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)
				Median	xx.x	xx.x	xx.x
				Min, Max	xx, xx	xx, xx	xx, xx
	Day -1		Value				
				N	xx	xx	xx
				Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)
				Median	xx.x	xx.x	xx.x
				Min, Max	xx, xx	xx, xx	xx, xx
	Day 1	Pre-dose	Value				
				N	xx	xx	xx
				Mean (SD)	xx (xx.x)	xx (xx.x)	xx (xx.x)
				Median	xx.x	xx.x	xx.x
				Min, Max	xx, xx	xx, xx	xx, xx
Etc.	Etc.						

PROGRAMMING NOTE: All visits outlined in Appendix A will be included.

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

APPENDIX D

PHARMACOKINETIC OUTPUTS SHELLS

Measured Human Plasma Concentrations of Lasmiditan, Normal Hepatic Function, CUD-P9-453

		Time (h)									
		0.00	**0.25**	**0.50**	**1.00**	**...**	**...**	**...**	**...**	**...**	**36.00**
Hepatic Function	**Subject**	**Concentration (ng/mL)**									
Normal	101 108										
	N **Mean** **SD** **Min** **Median** **Max** **CV%** **Geometric Mean** **Geometric CV%**										
BLQ : Below Limit of Quantitation **NC: Not Calculated**											

Similar tables will be presented for all hepatic groups

Cumulative Area Under the Curve of Lasmiditan, Normal Hepatic Function, CUD-P9-453

		Time (h)									
		0.00	0.25	0.50	1.00	...	...	...	...	...	36.00
Hepatic Function	**Subject**	**Cumulative AUC (ng*h/mL)**									
Normal	101 108										
	N										
	Mean										
	SD										
	Min										
	Median										
	Max										
	CV%										
	Geometric Mean										
	Geometric CV%										
NC: Not Calculated											

Similar tables will be presented for all hepatic groups and for urine data by intervals.

Pharmacokinetic Parameters of Lasmiditan, Normal Hepatic Function, CUD-P9-453

Hepatic Function	Subject	C_{max} (ng/mL)	T_{max} (h)	$AUC_{(0\text{-}Tlast)}$ (ng*h/mL)	$AUC_{(0\text{-}\infty)}$ (ng*h/mL)	$\%AUC_{(tlast\text{-}\infty)}$ (%)	$T_{1/2}$ (h)	CL/F (L/h)	V_z/F (L)
Normal	101								
	...								
	...								
	...								
	...								
	...								
	...								
	108								
	N								
	Mean		**NC**				**NC**		
	SD		**NC**				**NC**		
	Min								
	Median								
	Max								
	CV%		**NC**				**NC**		
	Geometric Mean		**NC**						
	Geometric CV%		**NC**						

Similar tables will be presented for all hepatic groups and for urine parameters.

Elimination Parameters of Lasmiditan, Normal Hepatic Function, CUD-P9-453

Hepatic Function	Subject	T_{LIN} (h)	T_{LQC} (h)	Number of Points	R^2	λ_z (1/h)
Normal	101					
	...					
	...					
	...					
	...					
	...					
	...					
	108					
	N					
	Mean					
	SD					
	Min					
	Median					
	Max					
	CV%					
	Geometric Mean					
	Geometric CV%					

A similar table will be presented for all hepatic groups.

Actual Sampling Time of Lasmiditan, Normal Hepatic Function, CUD-P9-453

		Time (h)													
		0.00	**0.25**	**0.50**	**1.00**	**...**	**...**	**...**	**...**	**...**	**...**	**...**	**...**	**...**	**36.00**
Hepatic Function	**Subject**	**Actual Time (h)**													
Normal	101 108														
	N **Mean** **SD** **Min** **Median** **Max** **CV%** **Geometric Mean** **Geometric CV%**														
NC: Not Calculated															

A similar table will be presented for all hepatic groups.

Pairwise Comparisons of Lasmiditan, CUD-P9-453

Parameters	Geometric LSmeans[a]		Comparison	Adjusted p-value	Ratio (%)	90% Confidence Limits (%)	
	Group					Lower	Upper
C_{max}	Mild (n=x) Moderate (n=x) Normal (n=x)		Mild vs Moderate Mild vs Normal Moderate vs Normal				
$AUC_{(0\text{-}tlast)}$	Mild (n=x) Moderate (n=x) Normal (n=x)		Mild vs Moderate Mild vs Normal Moderate vs Normal				
$AUC_{(0\text{-}\infty)}$	Mild (n=x) Moderate (n=x) Normal (n=x)		Mild vs Moderate Mild vs Normal Moderate vs Normal				

a C_{max} is presented in ng/mL, $AUC_{(0\text{-}tlast)}$ and $AUC_{(0\text{-}\infty)}$ are presented in ng*h/mL

Paired Comparisons of Tmax, Lasmiditan, CUD-P9-453

Parameter	Median (Range)		Comparison	P-value for Difference from Control	Hodges-Lehmann Median for Difference from Control	90% Confidence Limits for Difference from Control	
	Group					Lower	Upper
T_{max}	Mild (n=x) Moderate (n=x) Normal (n=x)		Mild vs Moderate Mild vs Normal Moderate vs Normal				

Tmax was analyzed using the Wilcoxon rank sum test

PHARMACOKINETIC FIGURES SHELLS

Figure 1: Linear Profile of the Mean of Lasmiditan in Plasma



The figure does not reflect the actual data of the study

Figure 2: Logarithmic Profile of the Mean of Lasmiditan in Plasma



The figure does not reflect the actual data of the study

Figures 2+1 to (2+1)+N: Individual Linear Profile of Lasmiditan in Plasma



The figure does not reflect the actual data of the study

Figure X: Individual Logarithmic Profile of Lasmiditan in Plasma



The figure does not reflect the actual data of the study

Figure N: Individual Elimination Profiles



The figure does not reflect the actual data of the study.

In Text Figure:

Figure 1: Linear Regression of ln-Transformed C_{max} vs Child-Pugh scores



The figure does not reflect the actual data of the study. Same graph will be presented for $AUC_{(0\text{-tlast})}$,$AUC_{(0\text{-}\infty)}$ and CL/F.

APPENDIX E

LISTING SHELLS

Listing 16.2.1
Listing of Study Disposition

Subject ID	Date of Completion or Discontinuation	Subject Status	Specify	AE #	Date of Death

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.2.1
Listing of PK Blood Sampling Time Deviations

Group	Elapsed Time (h)	Subject ID	Scheduled Date/Time	Actual Date/Time	Deviation (min)

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.3
Listing of Analysis Populations

Subject ID	Safety Population	PK Population	Reason if Excluded from one Population

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.4.1
Listing of Demographic Characteristics

Subject ID	Age	Date of Birth	Gender	Ethnicity	Race	Other Race	Weight (kg)	Height (cm)	BMI (kg/m^2)

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.4.2
Listing of Screen Failures

Subject ID	Date	Specify Primary Reason

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.5
Listing of Investigational Product Administration

Subject ID	Visit	Start Date/Time	Treatment	Dose Administered (mg)	Route	If Any Dosing Issues, Specify

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.7
Listing of Adverse Events

Subject ID	Visit/ Group/ AE #	SOC MedDRA Preferred Term Description of AE	Onset Date Time (Time since Last Dose)	Resolution Date Time (Duration)	S: Severity R: Relationship to Study Drug	O: Outcome S: Serious AE D: AE Leading To Discontinuation	Action Taken With Study Treatment / Other Action(s) Taken / Concomitant Given
	xxxxx	xxxxxxxxxxxx xxxxxxxxxxxx	YYYY-MM-DD/ HH:MM	YYYY-MM-DD/ HH:MM			
xxx	xxxxx	xxxxxxxxxxxx	(DD:HH:MM)	(DD:HH:MM)	xxxxxx	xxxxx	xxxxxx

Listing 16.2.8.1
Listing of Blood Chemistry

Subject ID	Lab Test Name (Units)	Reference Range	Visit	Date / Time	Value	Out-of-Range Flag	Assessment [1]

[1] NCS: Not Clinically Significant / CS: Clinically Significant / TBC: To Be Controlled.

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Similar listing(s):

L16.2.8.2	Listing of Hematology
L16.2.8.3	Listing of Urinalysis
L16.2.8.4	Listing of Urine Drug Screen
L16.2.8.5	Listing of Pregnancy Test
L16.2.8.6	Listing of Serology
L16.2.8.7	Listing of Endocrinology

Listing 16.2.9.1
Listing of Alcohol Habits

Subject ID	Intake Status	Quantity	Frequency	Start Date	End Date

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.9.2
Listing of Smoking Habits

Subject ID	Intake Status	Quantity	Frequency	Start Date	End Date

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.9.3
Listing of Prior Medication

Subject ID	#CM	Related to AE#/MH#	ATC / PT / Medication Name	Indication	Dose (unit)	Frequency	Formulation	Total Daily Dose	Route	Start Date/ Time	End Date/ Time

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Similar Listing:

Listing 16.2.9.4 Listing of Concomitant Medication

Listing 16.2.9.5
Listing of Physical Examination

Subject ID	Visit	Date / Time	Body System Examined	Result (Abnormal Findings)

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.9.6
Listing of Vital Signs

Subject ID	Visit	Timepoint	Position	Date / Time	Assessment (Units)	Value	Safety Review

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.9.7
Listing of ECG Assessments

Subject ID	Visit	Time Point	Date / Time	Position	Safety Review	Parameter (Unit)	Value
xxxxx	xxxxxx		YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
			YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
			YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
xxxxx	xxxxxx		YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		
xxxxx	xxxxxx		YYYY-MM-DD: HH:MM	xxxxxx	xxxxxx		

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.9.8
Listing of Inclusion/Exclusion Criteria Summary

Subject ID	Has the participant met all screening eligibility criteria?	Inclusion/Exclusion	Failed Criterion Number

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.9.9
Listing of Medical History

Subject ID	MH #	System Organ Class	MedDRA Preferred Term	Description of Medical History	Start Date	End Date

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Listing 16.2.9.10
Listing of Columbia-Suicide Severity Rating Scale (C-SSRS)

Subject ID	Visit	Category	Question	Answer

Date: VERSION – YYYY-MM-DD Data Source: XXXX Program Source: XXXXX.sas

Altasciences
CLINICAL RESEARCH

contact@altasciences.com
altasciences.com

Altasciences
CLINICAL RESEARCH
ALGORITHME PHARMA

575 Armand-Frappier Blvd.
Laval, Quebec
Canada H7V 4B3
450 973-6077
algopharm.com

Altasciences
CLINICAL RESEARCH
VINCE & ASSOCIATES

10103 Metcalf Ave.
Overland Park, KS 66212
United States
913 696-1601
vinceandassociates.com

Altasciences
CLINICAL RESEARCH
ALGORITHME PHARMA USA

4837 Amber Valley Parkway
Fargo, ND 58104
United States
701 551-3737
algopharm.com

16.1.9.2 Documentation of statistical analysis – SAS® output

Legend:
AUCinf= $AUC_{0-\infty}$
AUCT=$AUC_{0\text{-}Tlast}$
LambdaZ = λ_Z
Vz_F = V_z/F
CL_F = CL/F
lCmax= ln(C_{max})
lAUCT= ln($AUC_{0\text{-}Tlast}$)
lAUCinf= ln($AUC_{0-\infty}$)
lVz_F = ln(V_z/F)
lCL_F = ln (CL/F)
RkTmax= Rank of T_{max}

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

RAW DATA

---------- SUMMARY REPORT ----------

Hepatic Function Group=Mild

Obs	Subject ID	Cmax	Tmax	AUCT	AUCinf	Vz_F	Cl_F	LambdaZ	log{Cmax}	log{AUCT}
1	01401	159.00000	2.00000	1229.31750	1261.85792	1586.25544	158.49645	0.09992	5.06890	7.11421
2	01402	350.00000	0.75000	1629.60250	1673.31600	1370.20933	119.52315	0.08723	5.85793	7.39609
3	01404	125.00000	2.00000	978.55250	1007.61169	1257.71336	198.48916	0.15782	4.82831	6.88607
4	01408	518.00000	0.75000	2019.77500	2033.41542	507.28430	98.35668	0.19389	6.24998	7.61074
5	04101	255.00000	2.50000	2212.32550	2264.40458	855.45252	88.32344	0.10325	5.54126	7.70180
6	04102	258.00000	2.50000	1603.91250	1635.53001	744.38302	122.28452	0.16428	5.55296	7.38020
7	04105	220.00000	3.00000	1952.02000	2002.86802	1017.88226	99.85680	0.09810	5.39363	7.57662
8	04106	416.00000	1.50000	3229.05750	3318.46597	590.96250	60.26881	0.10198	6.03069	8.07995

Obs	log{AUCinf}	log{CLF}	log{LambdaZ}	log{Vz_F}	Rank{Tmax}	Child-Pugh classification	Individual Child-Pugh scores
1	7.14034	5.06573	-2.30340	7.36913	14.0	A	5
2	7.42256	4.78351	-2.43921	7.22272	2.0	A	5
3	6.91534	5.29073	-1.84632	7.13705	14.0	A	5
4	7.61747	4.58860	-1.64047	6.22907	2.0	A	6
5	7.72507	4.48101	-2.27063	6.75163	18.0	A	5
6	7.39972	4.80635	-1.80621	6.61256	18.0	A	5
7	7.60234	4.60374	-2.32174	6.92548	21.5	A	5
8	8.10726	4.09881	-2.28294	6.38175	8.0	A	5

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

RAW DATA

---------- SUMMARY REPORT ----------

Hepatic Function Group=Moderate

Obs	Subject ID	Cmax	Tmax	AUCT	AUCinf	Vz_F	Cl_F	LambdaZ	log{Cmax}	log{AUCT}
9	01403	207.00000	1.25000	960.51333	1008.11653	1898.74936	198.38976	0.10448	5.33272	6.86747
10	01405	259.00000	1.25000	1831.00000	1870.55382	1134.00305	106.92021	0.09429	5.55683	7.51262
11	01407	388.00000	1.50000	3600.06667	3810.94140	675.54883	52.48047	0.07769	5.96101	8.18871
12	01409	221.00000	1.00000	1883.79000	2010.53704	1368.73641	99.47591	0.07268	5.39816	7.54104
13	04104	359.00000	2.00000	2689.72500	2780.70989	806.74296	71.92408	0.08915	5.88332	7.89719
14	04107	419.00000	0.75000	3096.65500	3231.82927	774.07373	61.88446	0.07995	6.03787	8.03808
15	04108	143.00000	1.75000	971.09000	986.38429	1925.20006	202.76073	0.10532	4.96284	6.87842
16	04110	565.00000	1.50000	3696.07500	3825.60443	573.48982	52.27932	0.09116	6.33683	8.21503

Obs	log{AUCinf}	log{CLF}	log{LambdaZ}	log{Vz_F}	Rank{Tmax}	Child-Pugh classification	Individual Child-Pugh scores
9	6.91584	5.29023	-2.25872	7.54895	5.5	B	7
10	7.53399	4.67208	-2.36143	7.03351	5.5	B	8
11	8.24563	3.96044	-2.55508	6.51553	8.0	B	8
12	7.60616	4.59992	-2.62173	7.22164	4.0	B	8
13	7.93046	4.27561	-2.41739	6.69301	14.0	B	7
14	8.08080	4.12527	-2.52640	6.65167	2.0	B	7
15	6.89405	5.31203	-2.25076	7.56279	10.5	B	7
16	8.24947	3.95660	-2.39514	6.35174	8.0	B	7

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

RAW DATA

---------- SUMMARY REPORT ----------

Hepatic Function Group=Healthy

Obs	Subject ID	Cmax	Tmax	AUCT	AUCinf	Vz_F	Cl_F	LambdaZ	log{Cmax}	log{AUCT}
17	00102	199.00000	4.00000	1902.08500	1922.96133	816.67119	104.00625	0.12735	5.29330	7.55071
18	00103	307.00000	1.75000	1863.04750	1870.37367	703.84229	106.93050	0.15192	5.72685	7.52997
19	00104	216.00000	2.00000	1812.21750	1831.52555	887.40804	109.19859	0.12305	5.37528	7.50231
20	00111	270.00000	2.00000	1729.46000	1767.45418	770.47408	113.15711	0.14687	5.59842	7.45556
21	00114	189.00000	2.50000	1112.41750	1131.26315	1168.42476	176.79353	0.15131	5.24175	7.01429
22	00115	288.00000	2.53333	2136.05833	2146.74786	652.50784	93.16418	0.14278	5.66296	7.66672
23	00116	149.00000	3.00000	886.38500	916.53880	1680.43024	218.21226	0.12985	5.00395	6.78715
24	00119	192.00000	4.00000	1706.38150	1724.86484	957.16011	115.95111	0.12114	5.25750	7.44213

Obs	log{AUCinf}	log{CLF}	log{LambdaZ}	log{Vz_F}	Rank{Tmax}	Child-Pugh classification	Individual Child-Pugh scores
17	7.56162	4.64445	-2.06079	6.70524	23.5		
18	7.53389	4.67218	-1.88438	6.55655	10.5		
19	7.51290	4.69317	-2.09514	6.78830	14.0		
20	7.47730	4.72878	-1.91823	6.64701	14.0		
21	7.03109	5.17498	-1.88843	7.06341	18.0		
22	7.67171	4.53436	-1.94646	6.48082	20.0		
23	6.82060	5.38547	-2.04134	7.42681	21.5		
24	7.45290	4.75317	-2.11080	6.86397	23.5		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

DESCRIPTIVE RESULTS (OVERALL)

---------- SUMMARY REPORT ----------

Parameter	Hepatic Function Group	n	Min	Mean	Geometric Mean	Median	Max	Range	Standard Deviation	Coefficient of Variation
Cmax	Mild	8	125.00000	287.62500	261.24477	256.50000	518.00000	393.00000	132.53025	46.0774
Cmax	Moderate	8	143.00000	320.12500	294.03456	309.00000	565.00000	422.00000	138.14634	43.1539
Cmax	Healthy	8	149.00000	226.25000	220.30221	207.50000	307.00000	158.00000	55.57942	24.5655
Tmax	Mild	8	0.75000	1.87500	1.67942	2.00000	3.00000	2.25000	0.82375	43.9336
Tmax	Moderate	8	0.75000	1.37500	1.32021	1.37500	2.00000	1.25000	0.40089	29.1558
Tmax	Healthy	8	1.75000	2.72292	2.60613	2.51667	4.00000	2.25000	0.87962	32.3042
AUCT	Mild	8	978.55250	1856.82038	1751.47050	1790.81125	3229.05750	2250.50500	689.27918	37.1215
AUCT	Moderate	8	960.51333	2341.11438	2084.57232	2286.75750	3696.07500	2735.56167	1093.20227	46.6958
AUCT	Healthy	8	886.38500	1643.50654	1585.41976	1770.83875	2136.05833	1249.67333	423.04366	25.7403
AUCinf	Mild	8	1007.61169	1899.68370	1792.31256	1838.09201	3318.46597	2310.85427	706.91779	37.2124
AUCinf	Moderate	8	986.38429	2440.58459	2169.06192	2395.62347	3825.60443	2839.22013	1147.32299	47.0102
AUCinf	Healthy	8	916.53880	1663.96617	1608.01033	1799.48986	2146.74786	1230.20906	418.78659	25.1680
Vz_F	Mild	8	507.28430	991.26784	923.96469	936.66739	1586.25544	1078.97114	386.04048	38.9441
Vz_F	Moderate	8	573.48982	1144.56803	1040.39245	970.37300	1925.20006	1351.71024	537.99098	47.0038
Vz_F	Healthy	8	652.50784	954.61482	912.79750	852.03962	1680.43024	1027.92241	334.69340	35.0606
CL_F	Mild	8	60.26881	118.19988	111.58768	109.68998	198.48916	138.22035	43.20623	36.5535
CL_F	Moderate	8	52.27932	105.76437	92.20576	85.69999	202.76073	150.48141	61.87438	58.5021
CL_F	Healthy	8	93.16418	129.67669	124.37731	111.17785	218.21226	125.04808	43.83200	33.8010
LambdaZ	Mild	8	0.08723	0.12581	0.12077	0.10262	0.19389	0.10666	0.03990	31.7121
LambdaZ	Moderate	8	0.07268	0.08934	0.08863	0.09016	0.10532	0.03264	0.01204	13.4733
LambdaZ	Healthy	8	0.12114	0.13679	0.13626	0.13632	0.15192	0.03078	0.01281	9.3622
lCmax	Mild	8	4.82831	5.56546		5.54711	6.24998	1.42166	0.47671	8.5655
lCmax	Moderate	8	4.96284	5.68370		5.72008	6.33683	1.37398	0.44868	7.8942
lCmax	Healthy	8	5.00395	5.39500		5.33429	5.72685	0.72290	0.24766	4.5906
lAUCT	Mild	8	6.88607	7.46821		7.48636	8.07995	1.19387	0.36606	4.9016
lAUCT	Moderate	8	6.86747	7.64232		7.71912	8.21503	1.34756	0.54237	7.0969
lAUCT	Healthy	8	6.78715	7.36860		7.47894	7.66672	0.87957	0.30297	4.1117
lAUCinf	Mild	8	6.91534	7.49126		7.51245	8.10726	1.19192	0.36456	4.8664
lAUCinf	Moderate	8	6.89405	7.68205		7.76831	8.24947	1.35543	0.54720	7.1231
lAUCinf	Healthy	8	6.82060	7.38275		7.49510	7.67171	0.85110	0.29491	3.9946
lCLF	Mild	8	4.09881	4.71481		4.69362	5.29073	1.19192	0.36456	7.7322
lCLF	Moderate	8	3.95660	4.52402		4.43776	5.31203	1.35543	0.54720	12.0955
lCLF	Healthy	8	4.53436	4.82332		4.71097	5.38547	0.85110	0.29491	6.1143
lLambdaZ	Mild	8	-2.43921	-2.11386		-2.27678	-1.64047	0.79874	0.29964	-14.1749
lLambdaZ	Moderate	8	-2.62173	-2.42333		-2.40627	-2.25076	0.37097	0.13569	-5.5994
lLambdaZ	Healthy	8	-2.11080	-1.99319		-1.99390	-1.88438	0.22643	0.09391	-4.7114
lVz_F	Mild	8	6.22907	6.82867		6.83856	7.36913	1.14006	0.40774	5.9709
lVz_F	Moderate	8	6.35174	6.94735		6.86326	7.56279	1.21104	0.46548	6.7001
lVz_F	Healthy	8	6.48082	6.81651		6.74677	7.42681	0.94598	0.30656	4.4973
RkTmax	Mild	8	2.00000	12.18750	9.01672	14.00000	21.50000	19.50000	7.42552	60.9274
RkTmax	Moderate	8	2.00000	7.18750	6.23253	6.75000	14.00000	12.00000	3.80730	52.9711
RkTmax	Healthy	8	10.50000	18.12500	17.50009	19.00000	23.50000	13.00000	4.85320	26.7763

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=1 Param=Cmax

Model Information

Data Set	WORK.KINDATA
Dependent Variable	Value
Covariance Structure	Variance Components
Group Effect	FunctionGroup
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Model-Based
Degrees of Freedom Method	Between-Within

Class Level Information

Class	Levels	Values
FunctionGroup	3	1 2 3

Dimensions

Covariance Parameters	3
Columns in X	4
Columns in Z	0
Subjects	24
Max Obs per Subject	1

Number of Observations

Number of Observations Read	24
Number of Observations Used	24
Number of Observations Not Used	0

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	265.15407978	
1	1	259.49486652	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Group	Estimate
Residual	FunctionGroup 1	17564
Residual	FunctionGroup 2	19084
Residual	FunctionGroup 3	3089.07

Fit Statistics

-2 Res Log Likelihood	259.5
AIC (Smaller is Better)	265.5
AICC (Smaller is Better)	266.9
BIC (Smaller is Better)	269.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	5.66	0.0590

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
FunctionGroup	2	21	2.05	0.1536

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=1 Param=Cmax

Least Squares Means

Effect	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha	Lower	Upper
FunctionGroup	1	287.62	46.8565	21	6.14	<.0001	0.1	207.00	368.25
FunctionGroup	2	320.13	48.8421	21	6.55	<.0001	0.1	236.08	404.17
FunctionGroup	3	226.25	19.6503	21	11.51	<.0001	0.1	192.44	260.06

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Adjustment	Adj P	Alpha	Lower	Upper
FunctionGroup	1	2	-32.5000	67.6837	21	-0.48	0.6361	Tukey-Kramer	0.8814	0.1	-148.97	83.9663
FunctionGroup	1	3	61.3750	50.8101	21	1.21	0.2405	Tukey-Kramer	0.4617	0.1	-26.0561	148.81
FunctionGroup	2	3	93.8750	52.6468	21	1.78	0.0890	Tukey-Kramer	0.1995	0.1	3.2834	184.47

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Adj Lower	Adj Upper
FunctionGroup	1	2	-179.37	114.37
FunctionGroup	1	3	-48.8797	171.63
FunctionGroup	2	3	-20.3652	208.12

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=3 Param=AUCT

Model Information

Data Set	WORK.KINDATA
Dependent Variable	Value
Covariance Structure	Variance Components
Group Effect	FunctionGroup
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Model-Based
Degrees of Freedom Method	Between-Within

Class Level Information

Class	Levels	Values
FunctionGroup	3	1 2 3

Dimensions

Covariance Parameters	3
Columns in X	4
Columns in Z	0
Subjects	24
Max Obs per Subject	1

Number of Observations

Number of Observations Read	24
Number of Observations Used	24
Number of Observations Not Used	0

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	345.79800104	
1	1	339.95357919	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Group	Estimate
Residual	FunctionGroup 1	475106
Residual	FunctionGroup 2	1195091
Residual	FunctionGroup 3	178966

Fit Statistics

-2 Res Log Likelihood	340.0
AIC (Smaller is Better)	346.0
AICC (Smaller is Better)	347.4
BIC (Smaller is Better)	349.5

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	5.84	0.0538

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
FunctionGroup	2	21	1.51	0.2436

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=3 Param=AUCT

Least Squares Means

Effect	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha	Lower	Upper
FunctionGroup	1	1856.82	243.70	21	7.62	<.0001	0.1	1437.48	2276.16
FunctionGroup	2	2341.11	386.51	21	6.06	<.0001	0.1	1676.04	3006.19
FunctionGroup	3	1643.51	149.57	21	10.99	<.0001	0.1	1386.14	1900.88

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Adjustment	Adj P	Alpha	Lower	Upper
FunctionGroup	1	2	-484.29	456.92	21	-1.06	0.3012	Tukey-Kramer	0.5486	0.1	-1270.53	301.95
FunctionGroup	1	3	213.31	285.94	21	0.75	0.4639	Tukey-Kramer	0.7393	0.1	-278.71	705.33
FunctionGroup	2	3	697.61	414.44	21	1.68	0.1071	Tukey-Kramer	0.2348	0.1	-15.5299	1410.75

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Adj Lower	Adj Upper
FunctionGroup	1	2	-1475.78	507.19
FunctionGroup	1	3	-407.15	833.77
FunctionGroup	2	3	-201.69	1596.91

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=4 Param=AUCinf

Model Information

Data Set	WORK.KINDATA
Dependent Variable	Value
Covariance Structure	Variance Components
Group Effect	FunctionGroup
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Model-Based
Degrees of Freedom Method	Between-Within

Class Level Information

Class	Levels	Values
FunctionGroup	3	1 2 3

Dimensions

Covariance Parameters	3
Columns in X	4
Columns in Z	0
Subjects	24
Max Obs per Subject	1

Number of Observations

Number of Observations Read	24
Number of Observations Used	24
Number of Observations Not Used	0

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	347.35488834	
1	1	340.84221814	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Group	Estimate
Residual	FunctionGroup 1	499733
Residual	FunctionGroup 2	1316350
Residual	FunctionGroup 3	175382

Fit Statistics

-2 Res Log Likelihood	340.8
AIC (Smaller is Better)	346.8
AICC (Smaller is Better)	348.3
BIC (Smaller is Better)	350.4

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	6.51	0.0385

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
FunctionGroup	2	21	1.74	0.1991

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=4 Param=AUCinf

Least Squares Means

Effect	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha	Lower	Upper
FunctionGroup	1	1899.68	249.93	21	7.60	<.0001	0.1	1469.61	2329.75
FunctionGroup	2	2440.58	405.64	21	6.02	<.0001	0.1	1742.58	3138.59
FunctionGroup	3	1663.97	148.06	21	11.24	<.0001	0.1	1409.19	1918.75

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Adjustment	Adj P	Alpha	Lower	Upper
FunctionGroup	1	2	-540.90	476.46	21	-1.14	0.2691	Tukey-Kramer	0.5037	0.1	-1360.76	278.96
FunctionGroup	1	3	235.72	290.50	21	0.81	0.4262	Tukey-Kramer	0.7002	0.1	-264.16	735.59
FunctionGroup	2	3	776.62	431.82	21	1.80	0.0865	Tukey-Kramer	0.1944	0.1	33.5712	1519.67

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Adj Lower	Adj Upper
FunctionGroup	1	2	-1574.78	492.98
FunctionGroup	1	3	-394.65	866.08
FunctionGroup	2	3	-160.40	1713.64

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=8 Param=lCmax

Model Information

Data Set	WORK.KINDATA
Dependent Variable	Value
Covariance Structure	Variance Components
Group Effect	FunctionGroup
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Model-Based
Degrees of Freedom Method	Between-Within

Class Level Information

Class	Levels	Values
FunctionGroup	3	1 2 3

Dimensions

Covariance Parameters	3
Columns in X	4
Columns in Z	0
Subjects	24
Max Obs per Subject	1

Number of Observations

Number of Observations Read	24
Number of Observations Used	24
Number of Observations Not Used	0

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	27.77835282	
1	1	24.70196938	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Group	Estimate
Residual	FunctionGroup 1	0.2273
Residual	FunctionGroup 2	0.2013
Residual	FunctionGroup 3	0.06134

Fit Statistics

-2 Res Log Likelihood	24.7
AIC (Smaller is Better)	30.7
AICC (Smaller is Better)	32.1
BIC (Smaller is Better)	34.2

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	3.08	0.2148

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
FunctionGroup	2	21	1.42	0.2630

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=8 Param=lCmax

Least Squares Means

Effect	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha	Lower	Upper
FunctionGroup	1	5.5655	0.1685	21	33.02	<.0001	0.1	5.2754	5.8555
FunctionGroup	2	5.6837	0.1586	21	35.83	<.0001	0.1	5.4107	5.9567
FunctionGroup	3	5.3950	0.08756	21	61.61	<.0001	0.1	5.2443	5.5457

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Adjustment	Adj P	Alpha	Lower	Upper
FunctionGroup	1	2	-0.1182	0.2315	21	-0.51	0.6148	Tukey-Kramer	0.8669	0.1	-0.5165	0.2800
FunctionGroup	1	3	0.1705	0.1899	21	0.90	0.3796	Tukey-Kramer	0.6478	0.1	-0.1564	0.4973
FunctionGroup	2	3	0.2887	0.1812	21	1.59	0.1260	Tukey-Kramer	0.2704	0.1	-0.02309	0.6005

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Adj Lower	Adj Upper
FunctionGroup	1	2	-0.6205	0.3840
FunctionGroup	1	3	-0.2417	0.5826
FunctionGroup	2	3	-0.1045	0.6819

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=9 Param=lAUCT

Model Information

Data Set	WORK.KINDATA
Dependent Variable	Value
Covariance Structure	Variance Components
Group Effect	FunctionGroup
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Model-Based
Degrees of Freedom Method	Between-Within

Class Level Information

Class	Levels	Values
FunctionGroup	3	1 2 3

Dimensions

Covariance Parameters	3
Columns in X	4
Columns in Z	0
Subjects	24
Max Obs per Subject	1

Number of Observations

Number of Observations Read	24
Number of Observations Used	24
Number of Observations Not Used	0

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	29.02854090	
1	1	26.48128492	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Group	Estimate
Residual	FunctionGroup 1	0.1340
Residual	FunctionGroup 2	0.2942
Residual	FunctionGroup 3	0.09179

Fit Statistics

-2 Res Log Likelihood	26.5
AIC (Smaller is Better)	32.5
AICC (Smaller is Better)	33.9
BIC (Smaller is Better)	36.0

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	2.55	0.2798

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
FunctionGroup	2	21	0.80	0.4626

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=9 Param=lAUCT

Least Squares Means

Effect	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha	Lower	Upper
FunctionGroup	1	7.4682	0.1294	21	57.70	<.0001	0.1	7.2455	7.6909
FunctionGroup	2	7.6423	0.1918	21	39.85	<.0001	0.1	7.3124	7.9723
FunctionGroup	3	7.3686	0.1071	21	68.79	<.0001	0.1	7.1843	7.5529

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Adjustment	Adj P	Alpha	Lower	Upper
FunctionGroup	1	2	-0.1741	0.2313	21	-0.75	0.4600	Tukey-Kramer	0.7354	0.1	-0.5722	0.2240
FunctionGroup	1	3	0.09961	0.1680	21	0.59	0.5596	Tukey-Kramer	0.8254	0.1	-0.1895	0.3887
FunctionGroup	2	3	0.2737	0.2196	21	1.25	0.2264	Tukey-Kramer	0.4402	0.1	-0.1042	0.6517

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Adj Lower	Adj Upper
FunctionGroup	1	2	-0.6761	0.3279
FunctionGroup	1	3	-0.2649	0.4642
FunctionGroup	2	3	-0.2029	0.7503

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=10 Param=lAUCinf

Model Information

Data Set	WORK.KINDATA
Dependent Variable	Value
Covariance Structure	Variance Components
Group Effect	FunctionGroup
Estimation Method	REML
Residual Variance Method	None
Fixed Effects SE Method	Model-Based
Degrees of Freedom Method	Between-Within

Class Level Information

Class	Levels	Values
FunctionGroup	3	1 2 3

Dimensions

Covariance Parameters	3
Columns in X	4
Columns in Z	0
Subjects	24
Max Obs per Subject	1

Number of Observations

Number of Observations Read	24
Number of Observations Used	24
Number of Observations Not Used	0

Iteration History

Iteration	Evaluations	-2 Res Log Like	Criterion
0	1	29.00237589	
1	1	26.17053116	0.00000000

Convergence criteria met.

Covariance Parameter Estimates

Cov Parm	Group	Estimate
Residual	FunctionGroup 1	0.1329
Residual	FunctionGroup 2	0.2994
Residual	FunctionGroup 3	0.08697

Fit Statistics

-2 Res Log Likelihood	26.2
AIC (Smaller is Better)	32.2
AICC (Smaller is Better)	33.6
BIC (Smaller is Better)	35.7

Null Model Likelihood Ratio Test

DF	Chi-Square	Pr > ChiSq
2	2.83	0.2427

Type 3 Tests of Fixed Effects

Effect	Num DF	Den DF	F Value	Pr > F
FunctionGroup	2	21	0.96	0.3987

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

---------- SUMMARY REPORT ----------

The Mixed Procedure

Order=10 Param=lAUCinf

Least Squares Means

Effect	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Alpha	Lower	Upper
FunctionGroup	1	7.4913	0.1289	21	58.12	<.0001	0.1	7.2695	7.7130
FunctionGroup	2	7.6821	0.1935	21	39.71	<.0001	0.1	7.3491	8.0150
FunctionGroup	3	7.3828	0.1043	21	70.81	<.0001	0.1	7.2033	7.5622

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Estimate	Standard Error	DF	t Value	Pr > |t|	Adjustment	Adj P	Alpha	Lower	Upper
FunctionGroup	1	2	-0.1908	0.2325	21	-0.82	0.4210	Tukey-Kramer	0.6946	0.1	-0.5908	0.2092
FunctionGroup	1	3	0.1085	0.1658	21	0.65	0.5199	Tukey-Kramer	0.7919	0.1	-0.1768	0.3938
FunctionGroup	2	3	0.2993	0.2198	21	1.36	0.1877	Tukey-Kramer	0.3783	0.1	-0.07888	0.6775

Differences of Least Squares Means

Effect	Hepatic Function Group	Hepatic Function Group	Adj Lower	Adj Upper
FunctionGroup	1	2	-0.6952	0.3137
FunctionGroup	1	3	-0.2512	0.4683
FunctionGroup	2	3	-0.1776	0.7762

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

Geometric LSmeans

---------- SUMMARY REPORT ----------

Obs	Parameters	Group	GeoLSmeans
1	lCmax	Mild	261.24
2	lCmax	Moderate	294.03
3	lCmax	Normal	220.30
4	lAUCT	Mild	1751.47
5	lAUCT	Moderate	2084.57
6	lAUCT	Normal	1585.42
7	lAUCinf	Mild	1792.31
8	lAUCinf	Moderate	2169.06
9	lAUCinf	Normal	1608.01

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

ANOVA analysis

RATIO ESTIMATE BASED ON ln-TRANSFORMED PARAMETERS

---------- SUMMARY REPORT ----------

Obs	Parameters	Group	vs Group	Adj P-value	Ratio (%)	L90	U90
1	lCmax	1	2	0.8669	88.848	53.769	146.815
2	lCmax	1	3	0.6478	118.585	78.531	179.068
3	lCmax	2	3	0.2704	133.469	90.079	197.759
4	lAUCT	1	2	0.7354	84.021	50.859	138.804
5	lAUCT	1	3	0.8254	110.474	76.725	159.067
6	lAUCT	2	3	0.4402	131.484	81.636	211.770
7	lAUCinf	1	2	0.6946	82.631	49.896	136.842
8	lAUCinf	1	3	0.7919	111.462	77.784	159.720
9	lAUCinf	2	3	0.3783	134.891	83.728	217.318

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=AUCT

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	1007220	1007220	1.21	0.2893
Error	14	11622321	830166		
Corrected Total	15	12629542			

Root MSE	911.13435	R-Square	0.0798
Dependent Mean	2098.96738	Adj R-Sq	0.0140
Coeff Var	43.40870		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	791.05592	1209.05488	0.65	0.5235	-1802.10890	3384.22073
indiv	1	209.26583	189.98465	1.10	0.2893	-198.21071	616.74237

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=AUCT

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	1229	1837	329.0631	-608.0676	849.6	-0.716	*| |	0.038
2	1630	1837	329.0631	-207.7826	849.6	-0.245	| |	0.004
3	978.5525	1837	329.0631	-858.8326	849.6	-1.011	**| |	0.077
4	2020	2047	232.6827	-26.8759	880.9	-0.0305	| |	0.000
5	2212	1837	329.0631	374.9404	849.6	0.441	| |	0.015
6	1604	1837	329.0631	-233.4726	849.6	-0.275	| |	0.006
7	1952	1837	329.0631	114.6349	849.6	0.135	| |	0.001
8	3229	1837	329.0631	1392	849.6	1.638	| |***	0.201
9	960.5133	2256	268.6789	-1295	870.6	-1.488	**| |	0.105
10	1831	2465	403.0183	-634.1826	817.2	-0.776	*| |	0.073
11	3600	2465	403.0183	1135	817.2	1.389	| |**	0.235
12	1884	2465	403.0183	-581.3926	817.2	-0.711	*| |	0.062
13	2690	2256	268.6789	433.8082	870.6	0.498	| |	0.012
14	3097	2256	268.6789	840.7382	870.6	0.966	| |*	0.044
15	971.0900	2256	268.6789	-1285	870.6	-1.476	**| |	0.104
16	3696	2256	268.6789	1440	870.6	1.654	| |***	0.130
17	1902							
18	1863							
19	1812							
20	1729							
21	1112							
22	2136							
23	886.3850							
24	1706							

Sum of Residuals	0
Sum of Squared Residuals	11622321
Predicted Residual SS (PRESS)	15048631

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=AUCinf

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	1254768	1254768	1.39	0.2579
Error	14	12628107	902008		
Corrected Total	15	13882875			

Root MSE	949.74084	R-Square	0.0904
Dependent Mean	2170.13414	Adj R-Sq	0.0254
Coeff Var	43.76415		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	710.31943	1260.28482	0.56	0.5819	-1992.72268	3413.36153
indiv	1	233.57035	198.03465	1.18	0.2579	-191.17173	658.31244

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=AUCinf

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	1262	1878	343.0061	-616.3133	885.6	-0.696	*| |	0.036
2	1673	1878	343.0061	-204.8552	885.6	-0.231	| |	0.004
3	1008	1878	343.0061	-870.5595	885.6	-0.983	*| |	0.072
4	2033	2112	242.5419	-78.3261	918.2	-0.0853	| |	0.000
5	2264	1878	343.0061	386.2334	885.6	0.436	| |	0.014
6	1636	1878	343.0061	-242.6412	885.6	-0.274	| |	0.006
7	2003	1878	343.0061	124.6968	885.6	0.141	| |	0.001
8	3318	1878	343.0061	1440	885.6	1.626	|***	0.198
9	1008	2345	280.0633	-1337	907.5	-1.473	**| |	0.103
10	1871	2579	420.0949	-708.3284	851.8	-0.832	*| |	0.084
11	3811	2579	420.0949	1232	851.8	1.446	|**	0.254
12	2011	2579	420.0949	-568.3452	851.8	-0.667	*| |	0.054
13	2781	2345	280.0633	435.3980	907.5	0.480	| |	0.011
14	3232	2345	280.0633	886.5174	907.5	0.977	|*	0.045
15	986.3843	2345	280.0633	-1359	907.5	-1.497	**| |	0.107
16	3826	2345	280.0633	1480	907.5	1.631	|***	0.127
17	1923							
18	1870							
19	1832							
20	1767							
21	1131							
22	2147							
23	916.5388							
24	1725							

Sum of Residuals	0
Sum of Squared Residuals	12628107
Predicted Residual SS (PRESS)	16386093

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=CL_F

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	1572.52895	1572.52895	0.57	0.4644
Error	14	38913	2779.46872		
Corrected Total	15	40485			

Root MSE	52.72067	R-Square	0.0388
Dependent Mean	111.98212	Adj R-Sq	-0.0298
Coeff Var	47.07954		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	163.66128	69.95914	2.34	0.0347	13.61384	313.70872
indiv	1	-8.26867	10.99302	-0.75	0.4644	-31.84635	15.30902

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=CL_F

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	158.4964	122.3180	19.0405	36.1785	49.162	0.736	|*|	0.041
2	119.5232	122.3180	19.0405	-2.7948	49.162	-0.0568	|	0.000
3	198.4892	122.3180	19.0405	76.1712	49.162	1.549	|***	0.180
4	98.3567	114.0493	13.4636	-15.6926	50.973	-0.308	|	0.003
5	88.3234	122.3180	19.0405	-33.9945	49.162	-0.691	*|	0.036
6	122.2845	122.3180	19.0405	-0.0334	49.162	-0.0007	|	0.000
7	99.8568	122.3180	19.0405	-22.4611	49.162	-0.457	|	0.016
8	60.2688	122.3180	19.0405	-62.0491	49.162	-1.262	**|	0.119
9	198.3898	105.7806	15.5465	92.6091	50.376	1.838	|***	0.161
10	106.9202	97.5120	23.3197	9.4082	47.283	0.199	|	0.005
11	52.4805	97.5120	23.3197	-45.0315	47.283	-0.952	*|	0.110
12	99.4759	97.5120	23.3197	1.9640	47.283	0.0415	|	0.000
13	71.9241	105.7806	15.5465	-33.8565	50.376	-0.672	*|	0.022
14	61.8845	105.7806	15.5465	-43.8962	50.376	-0.871	*|	0.036
15	202.7607	105.7806	15.5465	96.9801	50.376	1.925	|***	0.176
16	52.2793	105.7806	15.5465	-53.5013	50.376	-1.062	**|	0.054
17	104.0063							
18	106.9305							
19	109.1986							
20	113.1571							
21	176.7935							
22	93.1642							
23	218.2123							
24	115.9511							

Sum of Residuals	0
Sum of Squared Residuals	38913
Predicted Residual SS (PRESS)	48950

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=Cmax

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	8057.83696	8057.83696	0.45	0.5149
Error	14	252708	18051		
Corrected Total	15	260766			

Root MSE	134.35239	R-Square	0.0309
Dependent Mean	303.87500	Adj R-Sq	-0.0383
Coeff Var	44.21305		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	186.89130	178.28262	1.05	0.3123	-195.48688	569.26948
indiv	1	18.71739	28.01441	0.67	0.5149	-41.36754	78.80233

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=Cmax

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	159.0000	280.4783	48.5224	-121.4783	125.3	-0.970	| *| |	0.071
2	350.0000	280.4783	48.5224	69.5217	125.3	0.555	| |* |	0.023
3	125.0000	280.4783	48.5224	-155.4783	125.3	-1.241	| **| |	0.116
4	518.0000	299.1957	34.3105	218.8043	129.9	1.684	| |*** |	0.099
5	255.0000	280.4783	48.5224	-25.4783	125.3	-0.203	| | |	0.003
6	258.0000	280.4783	48.5224	-22.4783	125.3	-0.179	| | |	0.002
7	220.0000	280.4783	48.5224	-60.4783	125.3	-0.483	| | |	0.017
8	416.0000	280.4783	48.5224	135.5217	125.3	1.082	| |** |	0.088
9	207.0000	317.9130	39.6184	-110.9130	128.4	-0.864	| *| |	0.036
10	259.0000	336.6304	59.4275	-77.6304	120.5	-0.644	| *| |	0.050
11	388.0000	336.6304	59.4275	51.3696	120.5	0.426	| | |	0.022
12	221.0000	336.6304	59.4275	-115.6304	120.5	-0.960	| *| |	0.112
13	359.0000	317.9130	39.6184	41.0870	128.4	0.320	| | |	0.005
14	419.0000	317.9130	39.6184	101.0870	128.4	0.787	| |* |	0.030
15	143.0000	317.9130	39.6184	-174.9130	128.4	-1.362	| **| |	0.088
16	565.0000	317.9130	39.6184	247.0870	128.4	1.925	| |*** |	0.176
17	199.0000							
18	307.0000							
19	216.0000							
20	270.0000							
21	189.0000							
22	288.0000							
23	149.0000							
24	192.0000							

Sum of Residuals	0
Sum of Squared Residuals	252708
Predicted Residual SS (PRESS)	316352

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=LambdaZ

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	0.00349	0.00349	3.50	0.0824
Error	14	0.01398	0.00099868		
Corrected Total	15	0.01748			

Root MSE	0.03160	R-Square	0.2000
Dependent Mean	0.10757	Adj R-Sq	0.1428
Coeff Var	29.37706		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	0.18461	0.04194	4.40	0.0006	0.09467	0.27456
indiv	1	-0.01233	0.00659	-1.87	0.0824	-0.02646	0.00181

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=LambdaZ

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	0.0999	0.1230	0.0114	-0.0231	0.0295	-0.783	*| |	0.046
2	0.0872	0.1230	0.0114	-0.0358	0.0295	-1.213	**| |	0.110
3	0.1578	0.1230	0.0114	0.0348	0.0295	1.182	|** |	0.105
4	0.1939	0.1107	0.008070	0.0832	0.0306	2.724	|***** |	0.259
5	0.1032	0.1230	0.0114	-0.0197	0.0295	-0.670	*| |	0.034
6	0.1643	0.1230	0.0114	0.0413	0.0295	1.401	|** |	0.147
7	0.0981	0.1230	0.0114	-0.0249	0.0295	-0.844	*| |	0.053
8	0.1020	0.1230	0.0114	-0.0210	0.0295	-0.713	*| |	0.038
9	0.1045	0.0983	0.009319	0.006156	0.0302	0.204	| |	0.002
10	0.0943	0.0860	0.0140	0.008283	0.0283	0.292	| |	0.010
11	0.0777	0.0860	0.0140	-0.008316	0.0283	-0.293	| |	0.010
12	0.0727	0.0860	0.0140	-0.0133	0.0283	-0.470	| |	0.027
13	0.0892	0.0983	0.009319	-0.009175	0.0302	-0.304	| |	0.004
14	0.0799	0.0983	0.009319	-0.0184	0.0302	-0.609	*| |	0.018
15	0.1053	0.0983	0.009319	0.006991	0.0302	0.232	| |	0.003
16	0.0912	0.0983	0.009319	-0.007169	0.0302	-0.237	| |	0.003
17	0.1274							
18	0.1519							
19	0.1231							
20	0.1469							
21	0.1513							
22	0.1428							
23	0.1299							
24	0.1211							

Sum of Residuals	0
Sum of Squared Residuals	0.01398
Predicted Residual SS (PRESS)	0.01726

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=RkTmax

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	152.63315	152.63315	4.91	0.0437
Error	14	434.80435	31.05745		
Corrected Total	15	587.43750			

Root MSE	5.57292	R-Square	0.2598
Dependent Mean	9.68750	Adj R-Sq	0.2070
Coeff Var	57.52693		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	25.78804	7.39514	3.49	0.0036	9.92704	41.64905
indiv	1	-2.57609	1.16203	-2.22	0.0437	-5.06840	-0.08377

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=RkTmax

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	14.0000	12.9076	2.0127	1.0924	5.197	0.210	| | |	0.003
2	2.0000	12.9076	2.0127	-10.9076	5.197	-2.099	|**** | |	0.330
3	14.0000	12.9076	2.0127	1.0924	5.197	0.210	| | |	0.003
4	2.0000	10.3315	1.4232	-8.3315	5.388	-1.546	|*** | |	0.083
5	18.0000	12.9076	2.0127	5.0924	5.197	0.980	| |* |	0.072
6	18.0000	12.9076	2.0127	5.0924	5.197	0.980	| |* |	0.072
7	21.5000	12.9076	2.0127	8.5924	5.197	1.653	| |***	0.205
8	8.0000	12.9076	2.0127	-4.9076	5.197	-0.944	| *| |	0.067
9	5.5000	7.7554	1.6434	-2.2554	5.325	-0.424	| | |	0.009
10	5.5000	5.1793	2.4650	0.3207	4.998	0.0642	| | |	0.001
11	8.0000	5.1793	2.4650	2.8207	4.998	0.564	| |* |	0.039
12	4.0000	5.1793	2.4650	-1.1793	4.998	-0.236	| | |	0.007
13	14.0000	7.7554	1.6434	6.2446	5.325	1.173	| |**	0.065
14	2.0000	7.7554	1.6434	-5.7554	5.325	-1.081	| **| |	0.056
15	10.5000	7.7554	1.6434	2.7446	5.325	0.515	| |* |	0.013
16	8.0000	7.7554	1.6434	0.2446	5.325	0.0459	| | |	0.000
17	23.5000							
18	10.5000							
19	14.0000							
20	14.0000							
21	18.0000							
22	20.0000							
23	21.5000							
24	23.5000							

Sum of Residuals	0
Sum of Squared Residuals	434.80435
Predicted Residual SS (PRESS)	554.34864

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=Vz_F

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	17826	17826	0.08	0.7823
Error	14	3145409	224672		
Corrected Total	15	3163235			

Root MSE	473.99586	R-Square	0.0056
Dependent Mean	1067.91793	Adj R-Sq	-0.0654
Coeff Var	44.38505		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	893.92274	628.98190	1.42	0.1771	-455.10926	2242.95473
indiv	1	27.83923	98.83497	0.28	0.7823	-184.14070	239.81916

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=Vz_F

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	1586	1033	171.1872	553.1365	442.0	1.251	| |** |	0.117
2	1370	1033	171.1872	337.0904	442.0	0.763	| |* |	0.044
3	1258	1033	171.1872	224.5945	442.0	0.508	| |* |	0.019
4	507.2843	1061	121.0476	-553.6738	458.3	-1.208	| ** | |	0.051
5	855.4525	1033	171.1872	-177.6664	442.0	-0.402	| | |	0.012
6	744.3830	1033	171.1872	-288.7359	442.0	-0.653	| *| |	0.032
7	1018	1033	171.1872	-15.2366	442.0	-0.0345	| | |	0.000
8	590.9625	1033	171.1872	-442.1564	442.0	-1.000	| ** | |	0.075
9	1899	1089	139.7738	809.9520	452.9	1.788	| |*** |	0.152
10	1134	1117	209.6606	17.3665	425.1	0.0409	| | |	0.000
11	675.5488	1117	209.6606	-441.0878	425.1	-1.038	| ** | |	0.131
12	1369	1117	209.6606	252.0998	425.1	0.593	| |* |	0.043
13	806.7430	1089	139.7738	-282.0544	452.9	-0.623	| *| |	0.018
14	774.0737	1089	139.7738	-314.7236	452.9	-0.695	| *| |	0.023
15	1925	1089	139.7738	836.4027	452.9	1.847	| |*** |	0.162
16	573.4898	1089	139.7738	-515.3075	452.9	-1.138	| ** | |	0.062
17	816.6712							
18	703.8423							
19	887.4080							
20	770.4741							
21	1168							
22	652.5078							
23	1680							
24	957.1601							

Sum of Residuals	0
Sum of Squared Residuals	3145409
Predicted Residual SS (PRESS)	3941589

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lAUCT

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	0.17827	0.17827	0.85	0.3725
Error	14	2.94011	0.21001		
Corrected Total	15	3.11839			

Root MSE	0.45827	R-Square	0.0572
Dependent Mean	7.55526	Adj R-Sq	-0.0102
Coeff Var	6.06552		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	7.00502	0.60811	11.52	<.0001	5.70075	8.30928
indiv	1	0.08804	0.09556	0.92	0.3725	-0.11691	0.29299

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lAUCT

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	7.1142	7.4452	0.1655	-0.3310	0.427	-0.775	| *| |	0.045
2	7.3961	7.4452	0.1655	-0.0491	0.427	-0.115	| | |	0.001
3	6.8861	7.4452	0.1655	-0.5591	0.427	-1.308	| **| |	0.128
4	7.6107	7.5333	0.1170	0.0775	0.443	0.175	| | |	0.001
5	7.7018	7.4452	0.1655	0.2566	0.427	0.600	| |* |	0.027
6	7.3802	7.4452	0.1655	-0.0650	0.427	-0.152	| | |	0.002
7	7.5766	7.4452	0.1655	0.1314	0.427	0.307	| | |	0.007
8	8.0799	7.4452	0.1655	0.6347	0.427	1.485	| |** |	0.165
9	6.8675	7.6213	0.1351	-0.7538	0.438	-1.722	| ***| |	0.141
10	7.5126	7.7093	0.2027	-0.1967	0.411	-0.479	| | |	0.028
11	8.1887	7.7093	0.2027	0.4794	0.411	1.166	| |** |	0.165
12	7.5410	7.7093	0.2027	-0.1683	0.411	-0.409	| | |	0.020
13	7.8972	7.6213	0.1351	0.2759	0.438	0.630	| |* |	0.019
14	8.0381	7.6213	0.1351	0.4168	0.438	0.952	| |* |	0.043
15	6.8784	7.6213	0.1351	-0.7429	0.438	-1.696	| ***| |	0.137
16	8.2150	7.6213	0.1351	0.5937	0.438	1.356	| |** |	0.088
17	7.5507							
18	7.5300							
19	7.5023							
20	7.4556							
21	7.0143							
22	7.6667							
23	6.7872							
24	7.4421							

Sum of Residuals	0
Sum of Squared Residuals	2.94011
Predicted Residual SS (PRESS)	3.74168

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lAUCinf

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	0.20718	0.20718	0.98	0.3394
Error	14	2.96475	0.21177		
Corrected Total	15	3.17193			

Root MSE	0.46018	R-Square	0.0653
Dependent Mean	7.58666	Adj R-Sq	-0.0014
Coeff Var	6.06568		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	6.99347	0.61065	11.45	<.0001	5.68375	8.30319
indiv	1	0.09491	0.09595	0.99	0.3394	-0.11089	0.30071

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lAUCinf

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	7.1403	7.4680	0.1662	-0.3277	0.429	-0.764	| *| |	0.044
2	7.4226	7.4680	0.1662	-0.0455	0.429	-0.106	| | |	0.001
3	6.9153	7.4680	0.1662	-0.5527	0.429	-1.288	| **| |	0.124
4	7.6175	7.5629	0.1175	0.0545	0.445	0.123	| | |	0.001
5	7.7251	7.4680	0.1662	0.2570	0.429	0.599	| |* |	0.027
6	7.3997	7.4680	0.1662	-0.0683	0.429	-0.159	| | |	0.002
7	7.6023	7.4680	0.1662	0.1343	0.429	0.313	| | |	0.007
8	8.1073	7.4680	0.1662	0.6392	0.429	1.490	| |** |	0.166
9	6.9158	7.6578	0.1357	-0.7420	0.440	-1.687	| ***| |	0.136
10	7.5340	7.7527	0.2036	-0.2188	0.413	-0.530	| *| |	0.034
11	8.2456	7.7527	0.2036	0.4929	0.413	1.194	| |** |	0.173
12	7.6062	7.7527	0.2036	-0.1466	0.413	-0.355	| | |	0.015
13	7.9305	7.6578	0.1357	0.2726	0.440	0.620	| |* |	0.018
14	8.0808	7.6578	0.1357	0.4230	0.440	0.962	| |* |	0.044
15	6.8940	7.6578	0.1357	-0.7638	0.440	-1.737	| ***| |	0.144
16	8.2495	7.6578	0.1357	0.5916	0.440	1.345	| |** |	0.086
17	7.5616							
18	7.5339							
19	7.5129							
20	7.4773							
21	7.0311							
22	7.6717							
23	6.8206							
24	7.4529							

Sum of Residuals	0
Sum of Squared Residuals	2.96475
Predicted Residual SS (PRESS)	3.77644

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lCLF

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	0.20718	0.20718	0.98	0.3394
Error	14	2.96475	0.21177		
Corrected Total	15	3.17193			

Root MSE	0.46018	R-Square	0.0653
Dependent Mean	4.61942	Adj R-Sq	-0.0014
Coeff Var	9.96191		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	5.21260	0.61065	8.54	<.0001	3.90289	6.52232
indiv	1	-0.09491	0.09595	-0.99	0.3394	-0.30071	0.11089

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lCLF

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	5.0657	4.7381	0.1662	0.3277	0.429	0.764	| |* |	0.044
2	4.7835	4.7381	0.1662	0.0455	0.429	0.106	| | |	0.001
3	5.2907	4.7381	0.1662	0.5527	0.429	1.288	| |** |	0.124
4	4.5886	4.6431	0.1175	-0.0545	0.445	-0.123	| | |	0.001
5	4.4810	4.7381	0.1662	-0.2570	0.429	-0.599	| *| |	0.027
6	4.8064	4.7381	0.1662	0.0683	0.429	0.159	| | |	0.002
7	4.6037	4.7381	0.1662	-0.1343	0.429	-0.313	| | |	0.007
8	4.0988	4.7381	0.1662	-0.6392	0.429	-1.490	| **| |	0.166
9	5.2902	4.5482	0.1357	0.7420	0.440	1.687	| |*** |	0.136
10	4.6721	4.4533	0.2036	0.2188	0.413	0.530	| |* |	0.034
11	3.9604	4.4533	0.2036	-0.4929	0.413	-1.194	| **| |	0.173
12	4.5999	4.4533	0.2036	0.1466	0.413	0.355	| | |	0.015
13	4.2756	4.5482	0.1357	-0.2726	0.440	-0.620	| *| |	0.018
14	4.1253	4.5482	0.1357	-0.4230	0.440	-0.962	| *| |	0.044
15	5.3120	4.5482	0.1357	0.7638	0.440	1.737	| |*** |	0.144
16	3.9566	4.5482	0.1357	-0.5916	0.440	-1.345	| **| |	0.086
17	4.6445							
18	4.6722							
19	4.6932							
20	4.7288							
21	5.1750							
22	4.5344							
23	5.3855							
24	4.7532							

Sum of Residuals	0
Sum of Squared Residuals	2.96475
Predicted Residual SS (PRESS)	3.77644

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lCmax

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	0.11320	0.11320	0.54	0.4751
Error	14	2.94268	0.21019		
Corrected Total	15	3.05588			

Root MSE	0.45847	R-Square	0.0370
Dependent Mean	5.62458	Adj R-Sq	-0.0317
Coeff Var	8.15113		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	5.18611	0.60837	8.52	<.0001	3.88127	6.49094
indiv	1	0.07016	0.09560	0.73	0.4751	-0.13488	0.27519

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lCmax

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	5.0689	5.5369	0.1656	-0.4680	0.428	-1.095	**| |	0.090
2	5.8579	5.5369	0.1656	0.3211	0.428	0.751	|* |	0.042
3	4.8283	5.5369	0.1656	-0.7086	0.428	-1.657	***| |	0.206
4	6.2500	5.6070	0.1171	0.6429	0.443	1.450	|** |	0.073
5	5.5413	5.5369	0.1656	0.004380	0.428	0.0102	| |	0.000
6	5.5530	5.5369	0.1656	0.0161	0.428	0.0376	| |	0.000
7	5.3936	5.5369	0.1656	-0.1433	0.428	-0.335	| |	0.008
8	6.0307	5.5369	0.1656	0.4938	0.428	1.155	|** |	0.100
9	5.3327	5.6772	0.1352	-0.3445	0.438	-0.786	*| |	0.029
10	5.5568	5.7473	0.2028	-0.1905	0.411	-0.463	| |	0.026
11	5.9610	5.7473	0.2028	0.2137	0.411	0.520	|* |	0.033
12	5.3982	5.7473	0.2028	-0.3492	0.411	-0.849	*| |	0.088
13	5.8833	5.6772	0.1352	0.2061	0.438	0.471	| |	0.011
14	6.0379	5.6772	0.1352	0.3607	0.438	0.823	|* |	0.032
15	4.9628	5.6772	0.1352	-0.7143	0.438	-1.631	***| |	0.127
16	6.3368	5.6772	0.1352	0.6596	0.438	1.506	|*** |	0.108
17	5.2933							
18	5.7268							
19	5.3753							
20	5.5984							
21	5.2417							
22	5.6630							
23	5.0039							
24	5.2575							

Sum of Residuals	0
Sum of Squared Residuals	2.94268
Predicted Residual SS (PRESS)	3.71153

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lLambdaZ

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	0.28942	0.28942	4.76	0.0466
Error	14	0.85103	0.06079		
Corrected Total	15	1.14045			

Root MSE	0.24655	R-Square	0.2538
Dependent Mean	-2.26860	Adj R-Sq	0.2005
Coeff Var	-10.86800		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	-1.56749	0.32717	-4.79	0.0003	-2.26920	-0.86579
indiv	1	-0.11218	0.05141	-2.18	0.0466	-0.22244	-0.00191

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lLambdaZ

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	-2.3034	-2.1284	0.0890	-0.1750	0.230	-0.761	*| |	0.043
2	-2.4392	-2.1284	0.0890	-0.3108	0.230	-1.352	**| |	0.137
3	-1.8463	-2.1284	0.0890	0.2821	0.230	1.227	|** |	0.113
4	-1.6405	-2.2406	0.0630	0.6001	0.238	2.517	|***** |	0.221
5	-2.2706	-2.1284	0.0890	-0.1422	0.230	-0.619	*| |	0.029
6	-1.8062	-2.1284	0.0890	0.3222	0.230	1.401	|** |	0.147
7	-2.3217	-2.1284	0.0890	-0.1934	0.230	-0.841	*| |	0.053
8	-2.2829	-2.1284	0.0890	-0.1546	0.230	-0.672	*| |	0.034
9	-2.2587	-2.3527	0.0727	0.0940	0.236	0.399	| |	0.008
10	-2.3614	-2.4649	0.1091	0.1035	0.221	0.468	| |	0.027
11	-2.5551	-2.4649	0.1091	-0.0902	0.221	-0.408	| |	0.020
12	-2.6217	-2.4649	0.1091	-0.1568	0.221	-0.709	*| |	0.061
13	-2.4174	-2.3527	0.0727	-0.0647	0.236	-0.274	| |	0.004
14	-2.5264	-2.3527	0.0727	-0.1737	0.236	-0.737	*| |	0.026
15	-2.2508	-2.3527	0.0727	0.1020	0.236	0.433	| |	0.009
16	-2.3951	-2.3527	0.0727	-0.0424	0.236	-0.180	| |	0.002
17	-2.0608							
18	-1.8844							
19	-2.0951							
20	-1.9182							
21	-1.8884							
22	-1.9465							
23	-2.0413							
24	-2.1108							

Sum of Residuals	0
Sum of Squared Residuals	0.85103
Predicted Residual SS (PRESS)	1.06423

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lVz_F

Number of Observations Read	24
Number of Observations Used	16
Number of Observations with Missing Values	8

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	1	0.00686	0.00686	0.04	0.8539
Error	14	2.72991	0.19499		
Corrected Total	15	2.73676			

Root MSE	0.44158	R-Square	0.0025
Dependent Mean	6.88801	Adj R-Sq	-0.0687
Coeff Var	6.41085		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	6.78010	0.58597	11.57	<.0001	5.52332	8.03687
indiv	1	0.01727	0.09208	0.19	0.8539	-0.18022	0.21475

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Individual Child-Pugh Scores at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lVz_F

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	7.3691	6.8664	0.1595	0.5027	0.412	1.221	| |** |	0.112
2	7.2227	6.8664	0.1595	0.3563	0.412	0.865	| |* |	0.056
3	7.1371	6.8664	0.1595	0.2706	0.412	0.657	| |* |	0.032
4	6.2291	6.8837	0.1128	-0.6546	0.427	-1.533	| ***| |	0.082
5	6.7516	6.8664	0.1595	-0.1148	0.412	-0.279	| | |	0.006
6	6.6126	6.8664	0.1595	-0.2539	0.412	-0.617	| *| |	0.029
7	6.9255	6.8664	0.1595	0.0590	0.412	0.143	| | |	0.002
8	6.3818	6.8664	0.1595	-0.4847	0.412	-1.177	| **| |	0.104
9	7.5490	6.9010	0.1302	0.6480	0.422	1.536	| |*** |	0.112
10	7.0335	6.9182	0.1953	0.1153	0.396	0.291	| | |	0.010
11	6.5155	6.9182	0.1953	-0.4027	0.396	-1.017	| **| |	0.126
12	7.2216	6.9182	0.1953	0.3034	0.396	0.766	| |* |	0.071
13	6.6930	6.9010	0.1302	-0.2080	0.422	-0.493	| | |	0.012
14	6.6517	6.9010	0.1302	-0.2493	0.422	-0.591	| *| |	0.017
15	7.5628	6.9010	0.1302	0.6618	0.422	1.569	| |*** |	0.117
16	6.3517	6.9010	0.1302	-0.5492	0.422	-1.302	| **| |	0.081
17	6.7052							
18	6.5566							
19	6.7883							
20	6.6470							
21	7.0634							
22	6.4808							
23	7.4268							
24	6.8640							

Sum of Residuals	0
Sum of Squared Residuals	2.72991
Predicted Residual SS (PRESS)	3.43815

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=AUCT

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	2044534	1022267	1.66	0.2144
Error	21	12944140	616388		
Corrected Total	23	14988674			

Root MSE	785.10359	R-Square	0.1364
Dependent Mean	1947.14710	Adj R-Sq	0.0542
Coeff Var	40.32071		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	1643.50654	277.57604	5.92	<.0001	1066.25558	2220.75751
GrpA	1	213.31383	392.55179	0.54	0.5926	-603.04231	1029.66998
GrpB	1	697.60783	392.55179	1.78	0.0900	-118.74831	1513.96398

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=AUCT

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	1229	1857	277.5760	-627.5029	734.4	-0.854	*| |	0.035
2	1630	1857	277.5760	-227.2179	734.4	-0.309	| |	0.005
3	978.5525	1857	277.5760	-878.2679	734.4	-1.196	**| |	0.068
4	2020	1857	277.5760	162.9546	734.4	0.222	| |	0.002
5	2212	1857	277.5760	355.5051	734.4	0.484	| |	0.011
6	1604	1857	277.5760	-252.9079	734.4	-0.344	| |	0.006
7	1952	1857	277.5760	95.1996	734.4	0.130	| |	0.001
8	3229	1857	277.5760	1372	734.4	1.869	|***|	0.166
9	960.5133	2341	277.5760	-1381	734.4	-1.880	***| |	0.168
10	1831	2341	277.5760	-510.1144	734.4	-0.695	*| |	0.023
11	3600	2341	277.5760	1259	734.4	1.714	|***|	0.140
12	1884	2341	277.5760	-457.3244	734.4	-0.623	*| |	0.018
13	2690	2341	277.5760	348.6106	734.4	0.475	| |	0.011
14	3097	2341	277.5760	755.5406	734.4	1.029	|**	0.050
15	971.0900	2341	277.5760	-1370	734.4	-1.866	***| |	0.166
16	3696	2341	277.5760	1355	734.4	1.845	|***|	0.162
17	1902	1644	277.5760	258.5785	734.4	0.352	| |	0.006
18	1863	1644	277.5760	219.5410	734.4	0.299	| |	0.004
19	1812	1644	277.5760	168.7110	734.4	0.230	| |	0.003
20	1729	1644	277.5760	85.9535	734.4	0.117	| |	0.001
21	1112	1644	277.5760	-531.0890	734.4	-0.723	*| |	0.025
22	2136	1644	277.5760	492.5518	734.4	0.671	|*	0.021
23	886.3850	1644	277.5760	-757.1215	734.4	-1.031	**| |	0.051
24	1706	1644	277.5760	62.8750	734.4	0.0856	| |	0.000

Sum of Residuals	0
Sum of Squared Residuals	12944140
Predicted Residual SS (PRESS)	16906632

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=AUCT

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	1022267	1.66	0.2144
Denominator	21	616388		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=AUCinf

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	2536727	1268364	1.91	0.1728
Error	21	13940255	663822		
Corrected Total	23	16476982			

Root MSE	814.75252	R-Square	0.1540
Dependent Mean	2001.41149	Adj R-Sq	0.0734
Coeff Var	40.70890		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	1663.96617	288.05852	5.78	<.0001	1064.91569	2263.01665
GrpA	1	235.71753	407.37626	0.58	0.5690	-611.46778	1082.90284
GrpB	1	776.61841	407.37626	1.91	0.0704	-70.56690	1623.80373

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=AUCinf

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	1262	1900	288.0585	-637.8258	762.1	-0.837	| *| |	0.033
2	1673	1900	288.0585	-226.3677	762.1	-0.297	| | |	0.004
3	1008	1900	288.0585	-892.0720	762.1	-1.170	| **| |	0.065
4	2033	1900	288.0585	133.7317	762.1	0.175	| | |	0.001
5	2264	1900	288.0585	364.7209	762.1	0.479	| | |	0.011
6	1636	1900	288.0585	-264.1537	762.1	-0.347	| | |	0.006
7	2003	1900	288.0585	103.1843	762.1	0.135	| | |	0.001
8	3318	1900	288.0585	1419	762.1	1.862	| |*** |	0.165
9	1008	2441	288.0585	-1432	762.1	-1.880	| ***| |	0.168
10	1871	2441	288.0585	-570.0308	762.1	-0.748	| *| |	0.027
11	3811	2441	288.0585	1370	762.1	1.798	| |*** |	0.154
12	2011	2441	288.0585	-430.0475	762.1	-0.564	| *| |	0.015
13	2781	2441	288.0585	340.1253	762.1	0.446	| | |	0.009
14	3232	2441	288.0585	791.2447	762.1	1.038	| |** |	0.051
15	986.3843	2441	288.0585	-1454	762.1	-1.908	| ***| |	0.173
16	3826	2441	288.0585	1385	762.1	1.817	| |*** |	0.157
17	1923	1664	288.0585	258.9952	762.1	0.340	| | |	0.005
18	1870	1664	288.0585	206.4075	762.1	0.271	| | |	0.003
19	1832	1664	288.0585	167.5594	762.1	0.220	| | |	0.002
20	1767	1664	288.0585	103.4880	762.1	0.136	| | |	0.001
21	1131	1664	288.0585	-532.7030	762.1	-0.699	| *| |	0.023
22	2147	1664	288.0585	482.7817	762.1	0.633	| |* |	0.019
23	916.5388	1664	288.0585	-747.4274	762.1	-0.981	| *| |	0.046
24	1725	1664	288.0585	60.8987	762.1	0.0799	| | |	0.000

Sum of Residuals	0
Sum of Squared Residuals	13940255
Predicted Residual SS (PRESS)	18207680

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=AUCinf

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	1268364	1.91	0.1728
Denominator	21	663822		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=CL_F

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	2288.42227	1144.21114	0.45	0.6432
Error	21	53315	2538.82052		
Corrected Total	23	55604			

Root MSE	50.38671	R-Square	0.0412
Dependent Mean	117.88031	Adj R-Sq	-0.0502
Coeff Var	42.74396		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	129.67669	17.81439	7.28	<.0001	92.62963	166.72375
GrpA	1	-11.47681	25.19335	-0.46	0.6534	-63.86926	40.91564
GrpB	1	-23.91232	25.19335	-0.95	0.3533	-76.30477	28.48013

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=CL_F

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	158.4964	118.1999	17.8144	40.2966	47.132	0.855	|*|	0.035
2	119.5232	118.1999	17.8144	1.3233	47.132	0.0281	|	0.000
3	198.4892	118.1999	17.8144	80.2893	47.132	1.703	|***|	0.138
4	98.3567	118.1999	17.8144	-19.8432	47.132	-0.421	|	0.008
5	88.3234	118.1999	17.8144	-29.8764	47.132	-0.634	*|	0.019
6	122.2845	118.1999	17.8144	4.0846	47.132	0.0867	|	0.000
7	99.8568	118.1999	17.8144	-18.3431	47.132	-0.389	|	0.007
8	60.2688	118.1999	17.8144	-57.9311	47.132	-1.229	**|	0.072
9	198.3898	105.7644	17.8144	92.6254	47.132	1.965	|***|	0.184
10	106.9202	105.7644	17.8144	1.1558	47.132	0.0245	|	0.000
11	52.4805	105.7644	17.8144	-53.2839	47.132	-1.131	**|	0.061
12	99.4759	105.7644	17.8144	-6.2885	47.132	-0.133	|	0.001
13	71.9241	105.7644	17.8144	-33.8403	47.132	-0.718	*|	0.025
14	61.8845	105.7644	17.8144	-43.8799	47.132	-0.931	*|	0.041
15	202.7607	105.7644	17.8144	96.9964	47.132	2.058	|****|	0.202
16	52.2793	105.7644	17.8144	-53.4850	47.132	-1.135	**|	0.061
17	104.0063	129.6767	17.8144	-25.6704	47.132	-0.545	*|	0.014
18	106.9305	129.6767	17.8144	-22.7462	47.132	-0.483	|	0.011
19	109.1986	129.6767	17.8144	-20.4781	47.132	-0.434	|	0.009
20	113.1571	129.6767	17.8144	-16.5196	47.132	-0.350	|	0.006
21	176.7935	129.6767	17.8144	47.1168	47.132	1.000	|*|	0.048
22	93.1642	129.6767	17.8144	-36.5125	47.132	-0.775	*|	0.029
23	218.2123	129.6767	17.8144	88.5356	47.132	1.878	|***|	0.168
24	115.9511	129.6767	17.8144	-13.7256	47.132	-0.291	|	0.004

Sum of Residuals	0
Sum of Squared Residuals	53315
Predicted Residual SS (PRESS)	69636

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=CL_F

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	1144.21114	0.45	0.6432
Denominator	21	2538.82052		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=Cmax

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	36362	18181	1.37	0.2753
Error	21	278164	13246		
Corrected Total	23	314526			

Root MSE	115.09091	R-Square	0.1156
Dependent Mean	278.00000	Adj R-Sq	0.0314
Coeff Var	41.39961		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	226.25000	40.69078	5.56	<.0001	141.62889	310.87111
GrpA	1	61.37500	57.54545	1.07	0.2983	-58.29732	181.04732
GrpB	1	93.87500	57.54545	1.63	0.1177	-25.79732	213.54732

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=Cmax

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	159.0000	287.6250	40.6908	-128.6250	107.7	-1.195	**| |	0.068
2	350.0000	287.6250	40.6908	62.3750	107.7	0.579	|* |	0.016
3	125.0000	287.6250	40.6908	-162.6250	107.7	-1.511	***| |	0.109
4	518.0000	287.6250	40.6908	230.3750	107.7	2.140	|****	0.218
5	255.0000	287.6250	40.6908	-32.6250	107.7	-0.303	| |	0.004
6	258.0000	287.6250	40.6908	-29.6250	107.7	-0.275	| |	0.004
7	220.0000	287.6250	40.6908	-67.6250	107.7	-0.628	*| |	0.019
8	416.0000	287.6250	40.6908	128.3750	107.7	1.192	|**	0.068
9	207.0000	320.1250	40.6908	-113.1250	107.7	-1.051	**| |	0.053
10	259.0000	320.1250	40.6908	-61.1250	107.7	-0.568	*| |	0.015
11	388.0000	320.1250	40.6908	67.8750	107.7	0.630	|* |	0.019
12	221.0000	320.1250	40.6908	-99.1250	107.7	-0.921	*| |	0.040
13	359.0000	320.1250	40.6908	38.8750	107.7	0.361	| |	0.006
14	419.0000	320.1250	40.6908	98.8750	107.7	0.918	|* |	0.040
15	143.0000	320.1250	40.6908	-177.1250	107.7	-1.645	***| |	0.129
16	565.0000	320.1250	40.6908	244.8750	107.7	2.275	|****	0.246
17	199.0000	226.2500	40.6908	-27.2500	107.7	-0.253	| |	0.003
18	307.0000	226.2500	40.6908	80.7500	107.7	0.750	|* |	0.027
19	216.0000	226.2500	40.6908	-10.2500	107.7	-0.0952	| |	0.000
20	270.0000	226.2500	40.6908	43.7500	107.7	0.406	| |	0.008
21	189.0000	226.2500	40.6908	-37.2500	107.7	-0.346	| |	0.006
22	288.0000	226.2500	40.6908	61.7500	107.7	0.574	|* |	0.016
23	149.0000	226.2500	40.6908	-77.2500	107.7	-0.718	*| |	0.025
24	192.0000	226.2500	40.6908	-34.2500	107.7	-0.318	| |	0.005

Sum of Residuals	0
Sum of Squared Residuals	278164
Predicted Residual SS (PRESS)	363317

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=Cmax

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	18181	1.37	0.2753
Denominator	21	13246		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=LambdaZ

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	0.00987	0.00494	7.79	0.0029
Error	21	0.01330	0.00063354		
Corrected Total	23	0.02318			

Root MSE	0.02517	R-Square	0.4259
Dependent Mean	0.11731	Adj R-Sq	0.3713
Coeff Var	21.45595		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	0.13679	0.00890	15.37	<.0001	0.11828	0.15529
GrpA	1	-0.01098	0.01259	-0.87	0.3929	-0.03715	0.01520
GrpB	1	-0.04745	0.01259	-3.77	0.0011	-0.07362	-0.02127

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=LambdaZ

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	0.0999	0.1258	0.008899	-0.0259	0.0235	-1.100	**| |	0.058
2	0.0872	0.1258	0.008899	-0.0386	0.0235	-1.639	***| |	0.128
3	0.1578	0.1258	0.008899	0.0320	0.0235	1.360	|** |	0.088
4	0.1939	0.1258	0.008899	0.0681	0.0235	2.892	|***** |	0.398
5	0.1032	0.1258	0.008899	-0.0226	0.0235	-0.958	*| |	0.044
6	0.1643	0.1258	0.008899	0.0385	0.0235	1.634	|*** |	0.127
7	0.0981	0.1258	0.008899	-0.0277	0.0235	-1.177	**| |	0.066
8	0.1020	0.1258	0.008899	-0.0238	0.0235	-1.012	**| |	0.049
9	0.1045	0.0893	0.008899	0.0151	0.0235	0.643	|* |	0.020
10	0.0943	0.0893	0.008899	0.004947	0.0235	0.210	| |	0.002
11	0.0777	0.0893	0.008899	-0.0117	0.0235	-0.495	| |	0.012
12	0.0727	0.0893	0.008899	-0.0167	0.0235	-0.708	*| |	0.024
13	0.0892	0.0893	0.008899	-0.000185	0.0235	-0.0079	| |	0.000
14	0.0799	0.0893	0.008899	-0.009393	0.0235	-0.399	| |	0.008
15	0.1053	0.0893	0.008899	0.0160	0.0235	0.679	|* |	0.022
16	0.0912	0.0893	0.008899	0.001821	0.0235	0.0773	| |	0.000
17	0.1274	0.1368	0.008899	-0.009431	0.0235	-0.401	| |	0.008
18	0.1519	0.1368	0.008899	0.0151	0.0235	0.643	|* |	0.020
19	0.1231	0.1368	0.008899	-0.0137	0.0235	-0.583	*| |	0.016
20	0.1469	0.1368	0.008899	0.0101	0.0235	0.428	| |	0.009
21	0.1513	0.1368	0.008899	0.0145	0.0235	0.617	|* |	0.018
22	0.1428	0.1368	0.008899	0.005993	0.0235	0.255	| |	0.003
23	0.1299	0.1368	0.008899	-0.006930	0.0235	-0.294	| |	0.004
24	0.1211	0.1368	0.008899	-0.0156	0.0235	-0.664	*| |	0.021

Sum of Residuals	0
Sum of Squared Residuals	0.01330
Predicted Residual SS (PRESS)	0.01738

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=LambdaZ

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	0.00494	7.79	0.0029
Denominator	21	0.00063354		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=Vz_F

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	162471	81235	0.44	0.6481
Error	21	3853369	183494		
Corrected Total	23	4015840			

Root MSE	428.36169	R-Square	0.0405
Dependent Mean	1030.15023	Adj R-Sq	-0.0509
Coeff Var	41.58245		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	954.61482	151.44873	6.30	<.0001	639.65995	1269.56969
GrpA	1	36.65302	214.18085	0.17	0.8658	-408.76043	482.06648
GrpB	1	189.95321	214.18085	0.89	0.3852	-255.46025	635.36666

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=Vz_F

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	1586	991.2678	151.4487	594.9876	400.7	1.485	|**|	0.105
2	1370	991.2678	151.4487	378.9415	400.7	0.946	|*|	0.043
3	1258	991.2678	151.4487	266.4455	400.7	0.665	|*|	0.021
4	507.2843	991.2678	151.4487	-483.9835	400.7	-1.208	|**|	0.069
5	855.4525	991.2678	151.4487	-135.8153	400.7	-0.339	| |	0.005
6	744.3830	991.2678	151.4487	-246.8848	400.7	-0.616	|*|	0.018
7	1018	991.2678	151.4487	26.6144	400.7	0.0664	| |	0.000
8	590.9625	991.2678	151.4487	-400.3053	400.7	-0.999	|*|	0.048
9	1899	1145	151.4487	754.1813	400.7	1.882	|***|	0.169
10	1134	1145	151.4487	-10.5650	400.7	-0.0264	| |	0.000
11	675.5488	1145	151.4487	-469.0192	400.7	-1.171	|**|	0.065
12	1369	1145	151.4487	224.1684	400.7	0.559	|*|	0.015
13	806.7430	1145	151.4487	-337.8251	400.7	-0.843	|*|	0.034
14	774.0737	1145	151.4487	-370.4943	400.7	-0.925	|*|	0.041
15	1925	1145	151.4487	780.6320	400.7	1.948	|***|	0.181
16	573.4898	1145	151.4487	-571.0782	400.7	-1.425	|**|	0.097
17	816.6712	954.6148	151.4487	-137.9436	400.7	-0.344	| |	0.006
18	703.8423	954.6148	151.4487	-250.7725	400.7	-0.626	|*|	0.019
19	887.4080	954.6148	151.4487	-67.2068	400.7	-0.168	| |	0.001
20	770.4741	954.6148	151.4487	-184.1407	400.7	-0.460	| |	0.010
21	1168	954.6148	151.4487	213.8099	400.7	0.534	|*|	0.014
22	652.5078	954.6148	151.4487	-302.1070	400.7	-0.754	|*|	0.027
23	1680	954.6148	151.4487	725.8154	400.7	1.811	|***|	0.156
24	957.1601	954.6148	151.4487	2.5453	400.7	0.00635	| |	0.000

Sum of Residuals	0
Sum of Squared Residuals	3853369
Predicted Residual SS (PRESS)	5032971

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=Vz_F

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	81235	0.44	0.6481
Denominator	21	183494		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lAUCT

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	0.30708	0.15354	0.89	0.4272
Error	21	3.63967	0.17332		
Corrected Total	23	3.94675			

Root MSE	0.41631	R-Square	0.0778
Dependent Mean	7.49304	Adj R-Sq	-0.0100
Coeff Var	5.55601		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	7.36860	0.14719	50.06	<.0001	7.06251	7.67470
GrpA	1	0.09961	0.20816	0.48	0.6372	-0.33328	0.53249
GrpB	1	0.27371	0.20816	1.31	0.2027	-0.15917	0.70660

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lAUCT

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	7.1142	7.4682	0.1472	-0.3540	0.389	-0.909	| *| |	0.039
2	7.3961	7.4682	0.1472	-0.0721	0.389	-0.185	| | |	0.002
3	6.8861	7.4682	0.1472	-0.5821	0.389	-1.495	| **| |	0.106
4	7.6107	7.4682	0.1472	0.1425	0.389	0.366	| | |	0.006
5	7.7018	7.4682	0.1472	0.2336	0.389	0.600	| |* |	0.017
6	7.3802	7.4682	0.1472	-0.0880	0.389	-0.226	| | |	0.002
7	7.5766	7.4682	0.1472	0.1084	0.389	0.278	| | |	0.004
8	8.0799	7.4682	0.1472	0.6117	0.389	1.571	| |*** |	0.118
9	6.8675	7.6423	0.1472	-0.7749	0.389	-1.990	| ***| |	0.189
10	7.5126	7.6423	0.1472	-0.1297	0.389	-0.333	| | |	0.005
11	8.1887	7.6423	0.1472	0.5464	0.389	1.403	| |** |	0.094
12	7.5410	7.6423	0.1472	-0.1013	0.389	-0.260	| | |	0.003
13	7.8972	7.6423	0.1472	0.2549	0.389	0.654	| |* |	0.020
14	8.0381	7.6423	0.1472	0.3958	0.389	1.016	| |** |	0.049
15	6.8784	7.6423	0.1472	-0.7639	0.389	-1.962	| ***| |	0.183
16	8.2150	7.6423	0.1472	0.5727	0.389	1.471	| |** |	0.103
17	7.5507	7.3686	0.1472	0.1821	0.389	0.468	| | |	0.010
18	7.5300	7.3686	0.1472	0.1614	0.389	0.414	| | |	0.008
19	7.5023	7.3686	0.1472	0.1337	0.389	0.343	| | |	0.006
20	7.4556	7.3686	0.1472	0.0870	0.389	0.223	| | |	0.002
21	7.0143	7.3686	0.1472	-0.3543	0.389	-0.910	| *| |	0.039
22	7.6667	7.3686	0.1472	0.2981	0.389	0.766	| |* |	0.028
23	6.7872	7.3686	0.1472	-0.5815	0.389	-1.493	| **| |	0.106
24	7.4421	7.3686	0.1472	0.0735	0.389	0.189	| | |	0.002

Sum of Residuals	0
Sum of Squared Residuals	3.63967
Predicted Residual SS (PRESS)	4.75386

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=lAUCT

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	0.15354	0.89	0.4272
Denominator	21	0.17332		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lAUCinf

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	0.36734	0.18367	1.06	0.3639
Error	21	3.63514	0.17310		
Corrected Total	23	4.00248			

Root MSE	0.41606	R-Square	0.0918
Dependent Mean	7.51869	Adj R-Sq	0.0053
Coeff Var	5.53361		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	7.38275	0.14710	50.19	<.0001	7.07685	7.68866
GrpA	1	0.10851	0.20803	0.52	0.6074	-0.32411	0.54113
GrpB	1	0.29930	0.20803	1.44	0.1650	-0.13332	0.73191

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lAUCinf

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	7.1403	7.4913	0.1471	-0.3509	0.389	-0.902	| *| |	0.039
2	7.4226	7.4913	0.1471	-0.0687	0.389	-0.177	| | |	0.001
3	6.9153	7.4913	0.1471	-0.5759	0.389	-1.480	| **| |	0.104
4	7.6175	7.4913	0.1471	0.1262	0.389	0.324	| | |	0.005
5	7.7251	7.4913	0.1471	0.2338	0.389	0.601	| |* |	0.017
6	7.3997	7.4913	0.1471	-0.0915	0.389	-0.235	| | |	0.003
7	7.6023	7.4913	0.1471	0.1111	0.389	0.285	| | |	0.004
8	8.1073	7.4913	0.1471	0.6160	0.389	1.583	| |*** |	0.119
9	6.9158	7.6821	0.1471	-0.7662	0.389	-1.969	| ***| |	0.185
10	7.5340	7.6821	0.1471	-0.1481	0.389	-0.380	| | |	0.007
11	8.2456	7.6821	0.1471	0.5636	0.389	1.448	| |** |	0.100
12	7.6062	7.6821	0.1471	-0.0759	0.389	-0.195	| | |	0.002
13	7.9305	7.6821	0.1471	0.2484	0.389	0.638	| |* |	0.019
14	8.0808	7.6821	0.1471	0.3988	0.389	1.025	| |** |	0.050
15	6.8940	7.6821	0.1471	-0.7880	0.389	-2.025	| ****| |	0.195
16	8.2495	7.6821	0.1471	0.5674	0.389	1.458	| |** |	0.101
17	7.5616	7.3828	0.1471	0.1789	0.389	0.460	| | |	0.010
18	7.5339	7.3828	0.1471	0.1511	0.389	0.388	| | |	0.007
19	7.5129	7.3828	0.1471	0.1302	0.389	0.334	| | |	0.005
20	7.4773	7.3828	0.1471	0.0945	0.389	0.243	| | |	0.003
21	7.0311	7.3828	0.1471	-0.3517	0.389	-0.904	| *| |	0.039
22	7.6717	7.3828	0.1471	0.2890	0.389	0.742	| |* |	0.026
23	6.8206	7.3828	0.1471	-0.5621	0.389	-1.444	| **| |	0.099
24	7.4529	7.3828	0.1471	0.0702	0.389	0.180	| | |	0.002

Sum of Residuals	0
Sum of Squared Residuals	3.63514
Predicted Residual SS (PRESS)	4.74794

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=lAUCinf

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	0.18367	1.06	0.3639
Denominator	21	0.17310		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lCLF

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	0.36734	0.18367	1.06	0.3639
Error	21	3.63514	0.17310		
Corrected Total	23	4.00248			

Root MSE	0.41606	R-Square	0.0918
Dependent Mean	4.68738	Adj R-Sq	0.0053
Coeff Var	8.87606		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	4.82332	0.14710	32.79	<.0001	4.51741	5.12923
GrpA	1	-0.10851	0.20803	-0.52	0.6074	-0.54113	0.32411
GrpB	1	-0.29930	0.20803	-1.44	0.1650	-0.73191	0.13332

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lCLF

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	5.0657	4.7148	0.1471	0.3509	0.389	0.902	|*|	0.039
2	4.7835	4.7148	0.1471	0.0687	0.389	0.177	|	0.001
3	5.2907	4.7148	0.1471	0.5759	0.389	1.480	|**	0.104
4	4.5886	4.7148	0.1471	-0.1262	0.389	-0.324	|	0.005
5	4.4810	4.7148	0.1471	-0.2338	0.389	-0.601	*|	0.017
6	4.8064	4.7148	0.1471	0.0915	0.389	0.235	|	0.003
7	4.6037	4.7148	0.1471	-0.1111	0.389	-0.285	|	0.004
8	4.0988	4.7148	0.1471	-0.6160	0.389	-1.583	***|	0.119
9	5.2902	4.5240	0.1471	0.7662	0.389	1.969	|***	0.185
10	4.6721	4.5240	0.1471	0.1481	0.389	0.380	|	0.007
11	3.9604	4.5240	0.1471	-0.5636	0.389	-1.448	**|	0.100
12	4.5999	4.5240	0.1471	0.0759	0.389	0.195	|	0.002
13	4.2756	4.5240	0.1471	-0.2484	0.389	-0.638	*|	0.019
14	4.1253	4.5240	0.1471	-0.3988	0.389	-1.025	**|	0.050
15	5.3120	4.5240	0.1471	0.7880	0.389	2.025	|****	0.195
16	3.9566	4.5240	0.1471	-0.5674	0.389	-1.458	**|	0.101
17	4.6445	4.8233	0.1471	-0.1789	0.389	-0.460	|	0.010
18	4.6722	4.8233	0.1471	-0.1511	0.389	-0.388	|	0.007
19	4.6932	4.8233	0.1471	-0.1302	0.389	-0.334	|	0.005
20	4.7288	4.8233	0.1471	-0.0945	0.389	-0.243	|	0.003
21	5.1750	4.8233	0.1471	0.3517	0.389	0.904	|*	0.039
22	4.5344	4.8233	0.1471	-0.2890	0.389	-0.742	*|	0.026
23	5.3855	4.8233	0.1471	0.5621	0.389	1.444	|**	0.099
24	4.7532	4.8233	0.1471	-0.0702	0.389	-0.180	|	0.002

Sum of Residuals	0
Sum of Squared Residuals	3.63514
Predicted Residual SS (PRESS)	4.74794

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=lCLF

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	0.18367	1.06	0.3639
Denominator	21	0.17310		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lCmax

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	0.33702	0.16851	1.03	0.3737
Error	21	3.42932	0.16330		
Corrected Total	23	3.76634			

Root MSE	0.40410	R-Square	0.0895
Dependent Mean	5.54805	Adj R-Sq	0.0028
Coeff Var	7.28373		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	5.39500	0.14287	37.76	<.0001	5.09788	5.69212
GrpA	1	0.17046	0.20205	0.84	0.4084	-0.24973	0.59065
GrpB	1	0.28870	0.20205	1.43	0.1678	-0.13149	0.70889

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lCmax

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	5.0689	5.5655	0.1429	-0.4966	0.378	-1.314	*| |	0.082
2	5.8579	5.5655	0.1429	0.2925	0.378	0.774	|* |	0.029
3	4.8283	5.5655	0.1429	-0.7371	0.378	-1.950	**| |	0.181
4	6.2500	5.5655	0.1429	0.6845	0.378	1.811	|***	0.156
5	5.5413	5.5655	0.1429	-0.0242	0.378	-0.0640	| |	0.000
6	5.5530	5.5655	0.1429	-0.0125	0.378	-0.0331	| |	0.000
7	5.3936	5.5655	0.1429	-0.1718	0.378	-0.455	| |	0.010
8	6.0307	5.5655	0.1429	0.4652	0.378	1.231	|**	0.072
9	5.3327	5.6837	0.1429	-0.3510	0.378	-0.929	*| |	0.041
10	5.5568	5.6837	0.1429	-0.1269	0.378	-0.336	| |	0.005
11	5.9610	5.6837	0.1429	0.2773	0.378	0.734	|* |	0.026
12	5.3982	5.6837	0.1429	-0.2855	0.378	-0.755	*| |	0.027
13	5.8833	5.6837	0.1429	0.1996	0.378	0.528	|* |	0.013
14	6.0379	5.6837	0.1429	0.3542	0.378	0.937	|* |	0.042
15	4.9628	5.6837	0.1429	-0.7209	0.378	-1.907	**| |	0.173
16	6.3368	5.6837	0.1429	0.6531	0.378	1.728	|***	0.142
17	5.2933	5.3950	0.1429	-0.1017	0.378	-0.269	| |	0.003
18	5.7268	5.3950	0.1429	0.3318	0.378	0.878	|* |	0.037
19	5.3753	5.3950	0.1429	-0.0197	0.378	-0.0522	| |	0.000
20	5.5984	5.3950	0.1429	0.2034	0.378	0.538	|* |	0.014
21	5.2417	5.3950	0.1429	-0.1533	0.378	-0.405	| |	0.008
22	5.6630	5.3950	0.1429	0.2680	0.378	0.709	|* |	0.024
23	5.0039	5.3950	0.1429	-0.3911	0.378	-1.035	*| |	0.051
24	5.2575	5.3950	0.1429	-0.1375	0.378	-0.364	| |	0.006

Sum of Residuals	0
Sum of Squared Residuals	3.42932
Predicted Residual SS (PRESS)	4.47911

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=lCmax

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	0.16851	1.03	0.3737
Denominator	21	0.16330		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lLambdaZ

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	0.78760	0.39380	10.10	0.0008
Error	21	0.81910	0.03900		
Corrected Total	23	1.60669			

Root MSE	0.19750	R-Square	0.4902
Dependent Mean	-2.17680	Adj R-Sq	0.4416
Coeff Var	-9.07279		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	-1.99319	0.06983	-28.55	<.0001	-2.13840	-1.84798
GrpA	1	-0.12067	0.09875	-1.22	0.2353	-0.32603	0.08469
GrpB	1	-0.43014	0.09875	-4.36	0.0003	-0.63549	-0.22478

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lLambdaZ

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	-2.3034	-2.1139	0.0698	-0.1895	0.185	-1.026	**| |	0.050
2	-2.4392	-2.1139	0.0698	-0.3253	0.185	-1.761	***| |	0.148
3	-1.8463	-2.1139	0.0698	0.2675	0.185	1.448	|** |	0.100
4	-1.6405	-2.1139	0.0698	0.4734	0.185	2.562	|***** |	0.313
5	-2.2706	-2.1139	0.0698	-0.1568	0.185	-0.849	*| |	0.034
6	-1.8062	-2.1139	0.0698	0.3077	0.185	1.665	|*** |	0.132
7	-2.3217	-2.1139	0.0698	-0.2079	0.185	-1.125	**| |	0.060
8	-2.2829	-2.1139	0.0698	-0.1691	0.185	-0.915	*| |	0.040
9	-2.2587	-2.4233	0.0698	0.1646	0.185	0.891	|* |	0.038
10	-2.3614	-2.4233	0.0698	0.0619	0.185	0.335	| |	0.005
11	-2.5551	-2.4233	0.0698	-0.1318	0.185	-0.713	*| |	0.024
12	-2.6217	-2.4233	0.0698	-0.1984	0.185	-1.074	**| |	0.055
13	-2.4174	-2.4233	0.0698	0.005937	0.185	0.0321	| |	0.000
14	-2.5264	-2.4233	0.0698	-0.1031	0.185	-0.558	*| |	0.015
15	-2.2508	-2.4233	0.0698	0.1726	0.185	0.934	|* |	0.042
16	-2.3951	-2.4233	0.0698	0.0282	0.185	0.153	| |	0.001
17	-2.0608	-1.9932	0.0698	-0.0676	0.185	-0.366	| |	0.006
18	-1.8844	-1.9932	0.0698	0.1088	0.185	0.589	|* |	0.017
19	-2.0951	-1.9932	0.0698	-0.1019	0.185	-0.552	*| |	0.014
20	-1.9182	-1.9932	0.0698	0.0750	0.185	0.406	| |	0.008
21	-1.8884	-1.9932	0.0698	0.1048	0.185	0.567	|* |	0.015
22	-1.9465	-1.9932	0.0698	0.0467	0.185	0.253	| |	0.003
23	-2.0413	-1.9932	0.0698	-0.0481	0.185	-0.261	| |	0.003
24	-2.1108	-1.9932	0.0698	-0.1176	0.185	-0.637	*| |	0.019

Sum of Residuals	0
Sum of Squared Residuals	0.81910
Predicted Residual SS (PRESS)	1.06984

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=lLambdaZ

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	0.39380	10.10	0.0008
Denominator	21	0.03900		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lVz_F

Number of Observations Read 24
Number of Observations Used 24

Analysis of Variance

Source	DF	Sum of Squares	Mean Square	F Value	Pr > F
Model	2	0.08360	0.04180	0.26	0.7713
Error	21	3.33827	0.15897		
Corrected Total	23	3.42187			

Root MSE	0.39870	R-Square	0.0244
Dependent Mean	6.86418	Adj R-Sq	-0.0685
Coeff Var	5.80848		

Parameter Estimates

Variable	DF	Parameter Estimate	Standard Error	t Value	Pr > |t|	95% Confidence Limits	
Intercept	1	6.81651	0.14096	48.36	<.0001	6.52336	7.10966
GrpA	1	0.01216	0.19935	0.06	0.9519	-0.40242	0.42674
GrpB	1	0.13084	0.19935	0.66	0.5187	-0.28374	0.54541

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1
Dependent Variable: Value

NAME OF FORMER VARIABLE=lVz_F

Output Statistics

Obs	Dependent Variable	Predicted Value	Std Error Mean Predict	Residual	Std Error Residual	Student Residual	-2-1 0 1 2	Cook's D
1	7.3691	6.8287	0.1410	0.5405	0.373	1.449	| |** |	0.100
2	7.2227	6.8287	0.1410	0.3940	0.373	1.057	| |** |	0.053
3	7.1371	6.8287	0.1410	0.3084	0.373	0.827	| |* |	0.033
4	6.2291	6.8287	0.1410	-0.5996	0.373	-1.608	| ***| |	0.123
5	6.7516	6.8287	0.1410	-0.0770	0.373	-0.207	| | |	0.002
6	6.6126	6.8287	0.1410	-0.2161	0.373	-0.579	| *| |	0.016
7	6.9255	6.8287	0.1410	0.0968	0.373	0.260	| | |	0.003
8	6.3818	6.8287	0.1410	-0.4469	0.373	-1.198	| **| |	0.068
9	7.5490	6.9474	0.1410	0.6016	0.373	1.613	| |*** |	0.124
10	7.0335	6.9474	0.1410	0.0862	0.373	0.231	| | |	0.003
11	6.5155	6.9474	0.1410	-0.4318	0.373	-1.158	| **| |	0.064
12	7.2216	6.9474	0.1410	0.2743	0.373	0.735	| |* |	0.026
13	6.6930	6.9474	0.1410	-0.2543	0.373	-0.682	| *| |	0.022
14	6.6517	6.9474	0.1410	-0.2957	0.373	-0.793	| *| |	0.030
15	7.5628	6.9474	0.1410	0.6154	0.373	1.650	| |*** |	0.130
16	6.3517	6.9474	0.1410	-0.5956	0.373	-1.597	| ***| |	0.121
17	6.7052	6.8165	0.1410	-0.1113	0.373	-0.298	| | |	0.004
18	6.5566	6.8165	0.1410	-0.2600	0.373	-0.697	| *| |	0.023
19	6.7883	6.8165	0.1410	-0.0282	0.373	-0.0756	| | |	0.000
20	6.6470	6.8165	0.1410	-0.1695	0.373	-0.455	| | |	0.010
21	7.0634	6.8165	0.1410	0.2469	0.373	0.662	| |* |	0.021
22	6.4808	6.8165	0.1410	-0.3357	0.373	-0.900	| *| |	0.039
23	7.4268	6.8165	0.1410	0.6103	0.373	1.636	| |*** |	0.128
24	6.8640	6.8165	0.1410	0.0475	0.373	0.127	| | |	0.001

Sum of Residuals	0
Sum of Squared Residuals	3.33827
Predicted Residual SS (PRESS)	4.36019

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

Regression Analysis of Group Child-Pugh Classification at Baseline

---------- SUMMARY REPORT ----------

The REG Procedure
Model: MODEL1

NAME OF FORMER VARIABLE=lVz_F

Test test_FunctionGroup Results for Dependent Variable Value

Source	DF	Mean Square	F Value	Pr > F
Numerator	2	0.04180	0.26	0.7713
Denominator	21	0.15897		

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

NON-PARAMETRIC TEST OF FIXED EFFECT for Tmax parameter

---------- SUMMARY REPORT ----------

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable Value
Classified by Variable FunctionGroup

FunctionGroup	N	Sum of Scores	Expected Under H0	Std Dev Under H0	Mean Score
2	8	38.50	68.0	9.465728	4.81250
3	8	97.50	68.0	9.465728	12.18750

Average scores were used for ties.

Wilcoxon Two-Sample Test

Statistic	38.5000
Normal Approximation	
Z	-3.0637
One-Sided Pr < Z	0.0011
Two-Sided Pr > |Z|	0.0022
t Approximation	
One-Sided Pr < Z	0.0039
Two-Sided Pr > |Z|	0.0079

Z includes a continuity correction of 0.5.

Kruskal-Wallis Test

Chi-Square	9.7126
DF	1
Pr > Chi-Square	0.0018

Hodges-Lehmann Estimation

Location Shift (2 - 3) -1.2500

Type	90% Confidence Limits		Interval Midpoint	Asymptotic Standard Error
Asymptotic (Moses)	-2.0000	-0.5333	-1.2667	0.4458
Exact	-2.0000	-0.7500	-1.3750	

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

NON-PARAMETRIC TEST OF FIXED EFFECT for Tmax parameter

---------- SUMMARY REPORT ----------

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable Value
Classified by Variable FunctionGroup

FunctionGroup	N	Sum of Scores	Expected Under H0	Std Dev Under H0	Mean Score
1	8	52.50	68.0	9.402127	6.56250
3	8	83.50	68.0	9.402127	10.43750

Average scores were used for ties.

Wilcoxon Two-Sample Test

Statistic	52.5000
Normal Approximation	
Z	-1.5954
One-Sided Pr < Z	0.0553
Two-Sided Pr > |Z|	0.1106
t Approximation	
One-Sided Pr < Z	0.0657
Two-Sided Pr > |Z|	0.1315

Z includes a continuity correction of 0.5.

Kruskal-Wallis Test

Chi-Square	2.7178
DF	1
Pr > Chi-Square	0.0992

Hodges-Lehmann Estimation

Location Shift (1 - 3) -1.0000

Type	90% Confidence Limits		Interval Midpoint	Asymptotic Standard Error
Asymptotic (Moses)	-1.7500	0.0000	-0.8750	0.5320
Exact	-1.7500	0.0000	-0.8750	

---------- SUMMARY REPORT ----------

Algorithme Pharma

CUD-P9-453: Effect of Hepatic Impairment on Pharmacokinetics of Lasmiditan

NON-PARAMETRIC TEST OF FIXED EFFECT for Tmax parameter

---------- SUMMARY REPORT ----------

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable Value
Classified by Variable FunctionGroup

FunctionGroup	N	Sum of Scores	Expected Under H0	Std Dev Under H0	Mean Score
1	8	81.0	68.0	9.423375	10.1250
2	8	55.0	68.0	9.423375	6.8750

Average scores were used for ties.

Wilcoxon Two-Sample Test

Statistic	81.0000

Normal Approximation

Z	1.3265
One-Sided Pr > Z	0.0923
Two-Sided Pr > |Z|	0.1847

t Approximation

One-Sided Pr > Z	0.1023
Two-Sided Pr > |Z|	0.2045

Z includes a continuity correction of 0.5.

Kruskal-Wallis Test

Chi-Square	1.9032
DF	1
Pr > Chi-Square	0.1677

Hodges-Lehmann Estimation

Location Shift (1 - 2) 0.5000

Type	90% Confidence Limits		Interval Midpoint	Asymptotic Standard Error
Asymptotic (Moses)	-0.2500	1.2500	0.5000	0.4560
Exact	0.0000	1.2500	0.6250	